AASLD
The Liver Meeting®

ELEVATE YOUR IMPACT AT THE LIVER MEETING®

2026 PROGRAM GUIDE
NOV. 5-9 // DENVER, CO





2026



© 2026 Zydus Therapeutics Inc. All rights reserved. DSE-US-0054-10/26

TABLE OF CONTENTS

PRESIDENT'S WELCOME 4

AASLD'S GLOBAL FOOTPRINT 5

MOBILE APP & TLMdX ACCESS 6

YOUR GUIDE TO #TLM26 7

AASLD FOUNDATION 8

2026 AASLD & AASLD FOUNDATION AWARDEES 10

CONVENTION CENTER MAPS 12

2026 NETWORKING EVENTS 16

NETWORKING LOUNGES 18

EXCLUSIVE AASLD MEMBER BENEFITS AT #TLM26 19

2026 PROGRAM: *ELEVATING* SCIENCE 20

2026 LIVER QUEST: PLAY TO WIN 54

2026 SPONSORS 55

2026 EXHIBIT HALL 56

PRESIDENT'S WELCOME

As the 2026 President of the American Association for the Study of Liver Diseases (AASLD), it is an honor to **welcome you to The Liver Meeting®** (TLM) in **Denver, Colorado, for the first time**.

This year, we are thrilled to welcome **members, clinicians, researchers, trainees, advocates, patients, and partners** who are joining us for five days of discovery, connection, and collaboration as we work together to **prevent and cure liver disease**.

We are here in the Mile High City, so our conference theme, ***ELEVATE***, feels especially meaningful. It reflects our shared commitment to raise the standard of liver disease care, expand what is possible through science, and bring new hope to the patients we serve.

TLM is more than a meeting; it is shaped by the people who make up our community. Our members and attendees bring their expertise, experience, and perspectives together to develop the program and advance the field with representation from more than **80 countries and 22 partner societies. TLM reflects the global community we serve.** Together, this network demonstrates what we can accomplish when we unite under a shared purpose, and why **AASLD is the trusted science leader in hepatology**.

The breadth of this year's program reflects the strength and diversity of this community. TLM26 offers more than **265 hours of opportunities to learn, share, and connect**. The program includes:

- **2,500+ posters** showcasing the latest science
- **39 Advanced Practice Provider (APP) sessions**, including new Case Report presentations
- **29 Community Conversations** designed for dialogue and connection
- **11 patient-focused sessions** bringing patient perspectives to TLM
- **Third annual Park @ TLM** with Inside the Journals, Hep Exchanges, and topic-based Meet-Up networking
- **Annual pickleball tournament** with a little collegial competition on the court – best of luck to my Virginia Commonwealth University (VCU) colleagues!

Five State-of-the-Art Lectures span hepatotoxicity, spatial omics, alcohol-associated liver disease care, transplant surgery, and the **President's Choice address by Dr. Peter Hotez**, a world leader and voice for professionalism in the current era of anti-science and anti-vaccine rhetoric.

TLM also reflects **how the practice of hepatology continues to evolve**.

- We are pleased to **welcome our APP program participants and patients**, with dedicated programming that brings their perspectives and expertise into the conversation.
- As more patients with liver disease are cared for outside of hepatology, we **recognized a need to provide frontline clinicians** with the knowledge and training to care for them. This weekend, we are putting that **commitment into action with the inaugural *Liver Care for Frontline Clinicians*** program, bringing liver education to the front line of patient care.

As we look ahead to **Philadelphia – Nov. 12-16, 2027** – we remain mindful of the global community we serve. This year and every year after, we intentionally structure the program to allow those observing Diwali to return home in time to celebrate with their families and communities.

Whether this is your first TLM or one of many, I hope you leave Denver energized with new ideas, meaningful connections, and a renewed sense of what we can accomplish together.

Thank you for your dedication to AASLD and to the people affected by liver disease. Together, let's continue to elevate hepatology and improve lives.

Warm regards,

SAUL J. KARPEN, MD, PHD, FAASLD
President, AASLD



AASLD'S GLOBAL FOOTPRINT

The Liver Meeting unites the world in hepatology with their global network of representing nearly **80 countries**.



AASLD and its global partners are united under one mission: to prevent and cure liver disease.

AAPA

acofp AMERICAN COLLEGE OF OSTEOPATHIC FAMILY PHYSICIANS

aga

ALEH

ASOCIACION MEXICANA DE HEPATOLOGIA

Asian Pacific Association for the Study of the Liver

ASGE

EASL™ The Home of Hepatology

EGA ETHIOPIAN GASTROENTEROLOGY ASSOCIATION

HKASLD

ILCA

ILTS INTERNATIONAL LIVER TRANSPLANTATION SOCIETY

INDIAN NATIONAL ASSOCIATION FOR STUDY OF THE LIVER INASL

JSH

KASL The Korean Association for the Study of the Liver

NASPGHAN

SASLT الجمعية السعودية لامراض وزراعة الكبد Saudi Society for the Study of Liver Disease and Transplantation

SOLDA SOCIETY ON LIVER DISEASE IN AFRICA

Taiwan Association for the Study of the Liver TASL

THAILAND ASSOCIATION FOR THE STUDY OF THE LIVER TASL 1992

#TLM26 IN THE PALM OF YOUR HAND

Your meeting, your schedule, your app — designed to keep you connected every step of the way.

COMPLIMENTARY WI-FI

Available throughout the convention center.

NETWORK/SSID: AASLD

PASSWORD: MASH2026

Sponsored by

Madrigal



RELIVE #TLM26 FROM ANYWHERE WITH TLMDX®

TLMdX® brings the science to you even after the meeting ends.
Access online sessions within 72 hours of the in-person presentation.

AASLD The Liver Meeting® NOV. 12–16, 2027

DIGITAL EXPERIENCE

YOUR GUIDE TO #TLM26

Essential event services to keep you connected, prepared, and on track.

BEACON TECHNOLOGY

AASLD is using event badge beacons to replace badge scanning. AASLD will match the beacon with your attendee ID to track sessions you attend, which will aggregate beacon data to gauge overall interest in content. Data captured will be used to determine traffic patterns, room capacities, and inform future event programming of The Liver Meeting®. All attendee data is confidential. No data or information will be distributed or shared externally by AASLD or the vendor (TurnoutNow). The data will be deleted 30 days after The Liver Meeting®, and no other third parties will have access to it. Attendees may request a badge without beacon technology. Visit the registration desk for assistance.

For more information on beacon technology, including how AASLD will utilize the data in real-time and in the future, visit The Liver Meeting website or registration desk onsite.

WI-FI

NETWORK: AASLD
PASSWORD: MASH2026

Sponsored by

Madrigal

FIRST AID

First Aid is available throughout the Convention Center during The Liver Meeting, located near Room 507 on the street level of the 500s meeting room corridor.

LOST & FOUND

Lost and left-behind items may be found at Onsite Registration, located in Lobby F. At the end of the meeting, all items will be turned over to the Colorado Convention Center security team.

IN CASE OF EMERGENCY

Dial 200 from any beige house phone inside the Convention Center or **call 303-228-8030** from your cell phone. If 911 is called, notify the Colorado Convention Center immediately of the nature and location of the emergency.

BAG & COAT CHECK

Bag & Coat Check, located in Lobby A near Onsite Registration, is available Thursday from 6:30 AM - 6 PM; Friday, Saturday and Sunday from 6:30 AM - 7:30 PM, and Monday from 7 AM - 12:30 PM. Please note, electronics are not permitted. **Bag & Coat Check will not be open for the Awards & Honors Gala.**

AASLD FOUNDATION

EMPOWERING THE NEXT GENERATION OF LEADERS IN HEPATOLOGY

AASLD Foundation is committed to fostering innovation and excellence in liver disease training and research to create a brighter and healthier tomorrow for patients and their families. **As a solely donor-funded organization, 100% of every dollar directly funds the future of hepatology** by supporting innovative research, career development, advanced training, and mentorship that equip the next generation of hepatologists to lead the field.

Together, we are accelerating discovery, strengthening the hepatology workforce, and advancing the understanding and treatment of liver disease.

View the 2026 grant recipients in lobby A foyer.

AWARDS & HONORS GALA

The Awards & Honors Gala is an unforgettable night honoring AASLD and AASLD Foundation awardees who are *ELEVATING* the field and community to new heights. This annual event recognizes and celebrates the leaders and awardees whose groundbreaking contributions are shaping hepatology today and inspiring the next generation.

Thank you to all those who attended and sponsored the Gala this year!

WALK OF HONOR

Now in its second year, the Walk of Honor recognizes a mentor, colleague, or leader in hepatology. Located outside Hall A/General Session, each tribute celebrates past legacies while supporting the future of hepatology. All proceeds directly fund AASLD Foundation's mission to advance research, education, and innovation in liver health.





CLUB 1950: SHAPING THE FUTURE OF HEPATOLOGY

Honoring AASLD's founding year, Club 1950 represents the pinnacle of leadership — a distinguished society of visionaries, trailblazers, and innovators who contribute $1,950+ annually. Members enjoy premier benefits at The Liver Meeting, including a dedicated registration desk, access to **the Club 1950 Member Lounge** — a private lounge offering full breakfast, lunch, refreshments, and premium amenities — reserved **General Session Club Seats**, and exclusive donor gifts.

Club 1950 is where leadership, legacy, and impact meet.

VIEW THE 2026 CLUB 1950 LIST ONLINE



VIP* DONOR ACCESS AT THE LIVER MEETING

We are proud to recognize our VIP donors who have contributed $500 or more to AASLD Foundation. As a special thank you, VIP Donors enjoy access to the VIP and Donor Lounge. A welcoming space to relax, connect, and recharge during the meeting.

JOIN THIS VALUED COMMUNITY BY DONATING ONLINE TODAY OR VISITING THE FOUNDATION BOOTH IN LOBBY A.



Exclusive to donors who made a gift of $500+ in 2026 or by special invitation.

CELEBRATING THE LEADERS, IN SHAPING LIVER HEALTH

AASLD DISTINGUISHED AWARDEES

Distinguished Achievement Award

Pere Ginès, MD, FAASLD

Distinguished Clinician Educator/Mentor Award

Tamar Taddei, MD, FAASLD

Distinguished Service Award

Frank Anania, MD, FAASLD

Distinguished Advocacy Award

Ricky Safer

AASLD IMPACT AWARDEES

Lily Dara, MD
Jennifer Lai, MD, MBA
Mazen Noureddin, MD, MHSc, FAASLD
Bernd Schnabl, MD, FAASLD
Elliot Tapper, MD, FAASLD

AASLD FOUNDATION EMERGING LIVER SCHOLARS ADVANCED PRACTICE PROVIDERS (ELAPP)

Maureen Carroll, AGPCNP-C
Monica Deitz, APRN, FNP-C
Elizabeth B. Hammond, MSN, APRN, FNP-C
Da Nine L. Hester-Harris, DNP, APRN, ANP-BC
Sue Hyon (Sue) Kim, MSN, RN
Ngan M. Nguyen, PharmD, BCACP
MaryKate O'Brien, MS, PA-C
Maggie Schiffhauer, MHS, PA-C
Neeyati Sheth, PA-C
Xong Yalo, DNP, APRN, AGNP-C

AASLD FOUNDATION EMERGING LIVER SCHOLARS (ELS) AWARDEES

Razan Aburumman, MD
Lauren Alpert, MD
Bishoi Aziz, MD, MSc
Theja V. Channapragada, DO, MBA, MS
John Donlan, MD
Caren Doueiry, MD, PhD
Fatima Elmustafa, MD
Leith Ghani, DO
Farinaz Ghodrati, MD
Prajwal Gowda, MD
Adel Hajj Ali, MD
Bima J. Hasjim, MD, MSc
Darya M. Herscovici, MD
Kimberly Ho, MD
Fayez J. Jabboure, MD
Basil Jalamneh, MD
Rohan Karkra, MBBS
Muhammad Ali Ibrahim Kazi, MD
Alexis J. Kim, MD
Mahesh Krishna, MD
Sienna D. Lila, MD
Husam Mikati, MD, MS
Guy Loic Nguefang Tchoukeu, MD, MPH
Cherechi Nwabueze, MBBS, MPH
Chelsea S. Pan, MD
Vitchapong Prasitsumrit, MD
Islam Rajab, MD
Rahul Sandella, MD
Jeevin Singh Sandhu, DO
Kaley Schwartz Levitt, MD
Sanjna Shelukar, MD
Elizabeth Townsend, MD, PhD
Renuka Verma, MD
Paul S. Yoon, MD
Ioannis A. Ziogas, MD, MPH

NOVATORS, AND ADVOCATES

AASLD FELLOWS AND ASSOCIATE FELLOWS

Faisal A. Abaalkhail, MBChB, FRCPC, FAASLD
John Scot Aita, MD, AGAF, FACG, FAASLD
Yasemin Hatice Balaban, MD, FAASLD
Po-Hung (Victor) Chen, MD, PhD, FACG, FASAM, FAASLD
Reena Cherian, DNP, FNP, PMHNP, AF-AASLD
Kathleen E. Corey, MD, MPH, MMSc, FAASLD
Amanda DeVoss, MMS, PA-C, AF-AASLD
Naveen Gara, MD, FAASLD
Nicole Gray, APRN-CNP, AF-AASLD
Edward W. Holt, MD, FAASLD
Jun Inoue, MD, PhD, FAASLD
Gary P. Jeffrey, MBBS, MD, FRACP, FRCP, FGESA, FAASLD
Savio John, MD, FAASLD
Eiji Kakazu, MD, PhD, FAASLD
Tatsuya Kanto, MD, PhD, FAASLD
Matthew Kappus, MD, FAASLD
Mandana Khalili, MD, MAS, FAASLD
Laurie Larson, APRN, CNP, AF-AASLD
Michael D. Leise, MD, FAASLD
Chih Wen Lin, MD, PhD, EMBA, FAASLD
Miguel H. Malespin, MD, AGAF, FAASLD
Martin W. Moehlen, MD, MPH, FAASLD
Khalid Mumtaz, MBBS, FCPS, MSc, FAASLD
Angelo H. Paredes, MD, FAASLD
Pallavi Patel, MD, FAASLD
Suzanne E. Robertazzi, DNP, ANP-BC, AF-AASLD
Manuel Romero-Gomez, MD, FAASLD
Hrishikesh V. Samant, MD, FACG, FAASLD
Marina Serper, MD, MS, FAASLD
Wai-Kay Seto, MD, MBBS, FRCP, AGAF, FAASLD
Kamran Shafiq, MBBS, MRCP, FRCP, FEBGH, MACG, FAASLD
Vicki Shah, PA-C, DMSc, MMS, AF-AASLD
Debbie L. Shawcross, BSc, MBBS, PhD, FRCP, FAASLD
Shivaram Prasad Singh, MBBS, MD, DM, FCGP, FSGEI, FINASL, FACG, AGAF, FRCP, FRCPS, FRCPI, Master-ISG, FAASLD
Acuthan Sourianarayanane, MD, MRCP, FAASLD
Timucin Taner, MD, PhD, FAASLD
George Therapondos, MBChB, MPH, FAASLD
Julius M. Wilder, MD, PhD, FAASLD
Grace Lai-Hung Wong, MD, MBChB, FRCP, FHKCP, FHKAM, FAASLD

PEOPLE AFFECTED BY LIVER DISEASE (PALD) TRAVEL AWARD RECIPIENTS


Congratulations to the inaugural PALD awardee recipients!


AASLD recognized 100 awardees with travel assistance to The Liver Meeting so their voices can be heard, experiences shared, and collaboration extended amongst our community.
Supported by a grant by Madrigal Pharmaceuticals

TO CELEBRATE THE AWARDEES ACHIEVEMENTS AT THE 2026 AASLD & AASLD FOUNDATION AWARDS & HONORS GALA, SCAN HERE.

NAVIGATING #TLM26


Navigate TLM using these maps to find sessions and key locations. This is your guide to getting around efficiently and making the most of your experience. For the most up-to-date maps, download the TLM mobile app.





2 EXHIBIT LEVEL
Restrooms
Elevators (Accessible)
Public Escalators
Public Stairs
Concessions
Emergency Stairs
1 LIVER LETTERS
2 WALK OF HONOR
CHAMPA STREET
Business Suites
The Park @ TLM
Hall D
Posters
Exhibits Hall EF
Up to Terrace Level
Down to Meeting Room Level By Lobby D
Down to Meeting Room Level By Lobby C
SPEER BOULEVARD (MOUNTAIN VIEW)
General Session Hall A
14TH STREET (CITY VIEW)
Down to Meeting Room Level By Lobby A
WELTON STREET

NAVIGATING #TLM26

Navigate TLM using these maps to find sessions and key locations. This is your guide to getting around efficiently and making the most of your experience. For the most up-to-date maps, download the TLM mobile app.



4 BALLROOM LEVEL



ELEVATE YOUR EXPERIENCE: #T

Attend dedicated networking events designed to spark meaningful conversations and lasting connections. *Check the mobile app for locations!*

THURSDAY, NOV. 5

7 - 8 AM	**Patient Welcome Breakfast,** Room 405 - 407
8 AM - NOON	**Liver Leaders Council (LLC) Summit @ TLM,** Room 403 - 404
2:30 - 3:30 PM	**Meet-Ups at The Park @ TLM** • First Timers, Summit 5 and 6
6 - 7 PM	**PRIDE Reception,** Hyatt Regency, Capitol Ballroom 4
7 - 7:45 PM	**Diversity Reception,** Hyatt Regency, Capitol Ballroom 1 - 3

EXPLORE INDUSTRY PROGRAMMING AT TLM26

Pick up your Industry Programming Guide at registration to view the complete schedule of TLM Theaters and Satellite Symposia.

FRIDAY, NOV. 6

9:45 - 10:45 AM	**Meet-Ups at The Park @ TLM** • Diversity, Summit 5 and 6
12:30 - 1 PM	**AASLD Leadership Luncheon,** Room 403 - 404
12:30 - 2 PM	**Advanced Practice Providers' Networking Lunch,** Room 405 - 407 *Supported by: Alfasigma, Ipsen, GSK, Gilead Sciences and Madrigal*
1 - 2 PM	**AASLD Annual Business Meeting** Room 403 - 404 **Meet-Ups at The Park @ TLM** • Emerging Liver Scholars Alumni, Summit 6
2 - 3 PM	**Emerging Liver APP Alumni Meet-Up** Associates Lounge
5 - 6:30 PM	**Exhibit Hall Opening Reception,** Exhibit Hall DEF *Supported by: Mirum Pharmaceuticals*
7 - 8 PM	**Fellows' Reception,** Denver Art Museum
7:30 - 11:30 PM	**Members' Reception,** Denver Art Museum *Supported by: Elevar Therapeutics, Inventiva, and Mirum Pharmaceuticals*

By invitation only. *Ticket required.* *AASLD members only.* *Fellow and Associate Fellow members only.*

TLM26 NETWORKING EVENTS

SATURDAY, NOV. 7

9:45 - 10:45 AM	**Meet-Ups at The Park @ TLM** • Liver Fellow Network Alumni, Summit 5 and 6
12:30 - 2 PM	**AASLD Past Presidents' Luncheon,** Room 403 - 404
3:45 - 4:45 PM	**Meet-Ups at The Park @ TLM** • ALEH, Summit 5
5:45 - 6:45 PM	**Hepatology Associates' Reception,** Hepatology Associates Lounge *Supported by: Gilead Sciences, GSK, Madrigal, Mirum Pharmaceuticals and Novo Nordisk*
7:30 - 9 PM	**Awards & Honors Gala,** Exhibit Hall A

SUNDAY, NOV. 8

7 - 8 AM	**Early Career Coffee & Connections hosted by the Liver Fellow Network,** Room 405 - 407
9:45 - 10:45 AM	**Meet-Ups at The Park @ TLM** • AASLD/EASL Masterclass, Summit 5 • Clinician and Medical Educators, Summit 6
12:30 - 2 PM	**Women's Networking Luncheon,** Room 405 - 407 *Supported by: Gilead Sciences and Madrigal*

2026 TLM MEDIA PARTNERS



Open to all Hepatology Associate Attendees.

NETWORKING LOUNGES

CLUB 1950 ROOM 401 - 402

Club 1950 members enjoy premier benefits at The Liver Meeting, including access to the Club 1950 Member Lounge. A private lounge offering full breakfast, lunch, refreshments, and premium amenities

HEPATOLOGY ASSOCIATES LOUNGE ROOM 302

Take a break at the Convention Center in Room 302. Meet fellow hepatology associates and recharge in the Hepatology Associates Lounge. Open to both AASLD members and non-members. *Supported by: Gilead Sciences and Madrigal*

MEMBER LOUNGE ROOM 301

Enjoy a quiet space to network, work, or unwind between sessions at the AASLD Member Lounge.

PATIENT LOUNGE MILE HIGH BALLROOM 4BC

Take a moment to connect, recharge, and find support at the Patient & Patient Advocates Lounge. A welcoming space to connect with others and access patient resources available throughout The Liver Meeting. *Supported by: Boehringer Ingelheim, Eisai, Inc. and Elevar Therapeutics*

VIP AND DONOR LOUNGE ROOM 303

VIP donors enjoy access to the VIP and Donor Lounge, a welcoming space to relax, connect, and recharge during the meeting.

SIG MEMBERSHIP MEETINGS

Are you a SIG member? Or interested in joining a SIG? Be sure to join us at your respective SIG membership meeting(s) during TLM! These meetings are a great opportunity to connect with SIG leaders and fellow members, discuss specialty-specific topics, and contribute to planning next year's sessions.





EXCLUSIVE MEMBER BENEFITS AT #TLM26

AASLD MEMBER LOUNGE

Enjoy a quiet space to network, work, or unwind between sessions at the Member Lounge located in room 301, open Thursday through Sunday from 7 AM to 6 PM.

AASLD MEMBERS' RECEPTION

At the Denver Art Museum on Nov. 6 from 7:30 - 11:30 PM, mingle with passionate colleagues, interact with our leadership, and forge new, but lasting connections.

SHARE YOUR EXCITEMENT ON SOCIAL

Stay ahead in liver health and connect with colleagues online — tag AASLD and use #TLM26 in your posts to double the IMPACT.

- **@AASLDNews**
- **@AASLDTweets**
- **@AASLDNews**
- **@AASLD**
- **@AASLD**

SPIN TO WIN!

TEST YOUR AASLD KNOWLEDGE

Visit the AASLD & AASLD Foundation Booth in Lobby A, parallel to registration, for a fun and interactive game that will put your AASLD knowledge to the test! **Win exclusive giveaways, including a tech cleaning kit, humidifier, salad shaker, travel organizer, and more.**

BECOME A MEMBER TODAY!

AASLD MEMBERSHIP

ONE PROGRAM. ELEVATING SCIEN

Make the most of every opportunity to learn, network, and expand your knowledge at #TLM26 with this comprehensive guide. Download the mobile app for the most up-to-date information, as session details are current as of October 2, 2026.

THURSDAY, NOVEMBER 5

7 – 8 AM

Patient Welcome Breakfast

Convention Center: Room 405 - 407

The Patient Welcome Breakfast kicks off the patient attendee experience at The Liver Meeting. Patients, caregivers, and advocates are invited to participate!

8 – 9:30 AM

Elevate Your Understanding: What Your Liver Wants You to Know

Convention Center: Mile High Ballroom 4DEF

This interactive, patient-centered session is designed to elevate knowledge, confidence, and engagement around liver health, liver disease, and liver cancer. Program presenters aim to empower patients, caregivers, and advocates by providing clear, accessible education about how the liver functions, why liver health matters to overall well-being, and how individuals can take an active role in prevention, treatment, and decision-making.

8 AM – Noon

Liver Leaders Council Summit @ TLM

Convention Center: Room 403 - 404

This invitation only meeting will focus on emerging issues across the spectrum of Liver Disease, bringing together industry, member-leader experts, regulators, and patients/patient advocacy groups to engage in strategic conversations around shared opportunities and challenges.

8 AM – 5 PM

Basic Science Symposium, Parts 1–4: Protein Quality Control, the Unfolded Protein Response, and Endoplasmic Reticulum Stress in Acute and Chronic Liver Disease

Convention Center: Bluebird Ballroom 1A

This basic science symposium explores the fundamentals of and latest advances in endoplasmic reticulum (ER) stress and proteostasis in the pathophysiology of liver injury and chronic liver disease. Potential opportunities for translation of these advances into novel therapeutics are also explored.

Postgraduate Course, Parts 1–4: Advancing Hepatology—Breakthroughs Shaping Tomorrow's Care

Convention Center: Hall A

Part 1: Liver Fat Comes Out of the Shadows-Transforming Care in Steatotic Liver Disease Steatotic liver disease now represents the most prevalent spectrum of liver disorders encountered in clinical practice worldwide. Rapid advances in disease nomenclature, epidemiology, pathophysiology, and therapeutics have fundamentally changed how clinicians evaluate and manage these patients.

9:30 – 10 AM

Alcohol-associated Liver Disease (ALD) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Alcohol-associated Liver Disease (ALD) SIG.

Inside the Journals: Clinical Trials in ACLF

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Anand V. Kulkarni, MD, DM

10 – 10:30 AM

Clinical Practice SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Clinical Practice SIG.

Inside the Journals: Rehab, Exercise, and Transportation Trials

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Kali Zhou, MD, MA

By invitation only. *Ticket required.* *AASLD members only.*

THURSDAY, NOVEMBER 5

11 AM – 12:30 PM

Breaking the Hush: The HOPE Within Alcohol-Associated Liver Disease

Convention Center: Mile High Ballroom 4DEF

Join this thought-provoking session which addresses key questions and approaches to overcome social and medical stigma to improve outcomes for persons living with alcohol-associated liver disease (ALD).

NOON – 1 PM

Thursday Poster Presenter Presentation Hour

Convention Center: Poster Hall, Hall DE

The following poster categories will be in the Poster Hall:

- Portal Hypertension and Other Complications of Cirrhosis
- MASLD - Experimental: Basic
- Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis
- Cell and Molecular Biology
- Genomics and Precision Medicine
- Gut Liver Axis and Microbiome
- Human Cholestatic and Autoimmune Liver Diseases
- Metabolic and Genetic Disease
- Vascular Liver Disease, Hemostasis and Thrombosis

NOON – 1:30 PM

Cases of Confounding Cholestasis: Navigating the Diagnostic and Therapeutic Challenges of PFICs

Supported by: Ipsen
Organized by: Clinical Care Options, LLC dba Decera Clinical Education in partnership with Progressive Familial Intrahepatic Cholestasis (PFIC) Network

Convention Center: Four Seasons Ballroom 4

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) are rare, heritable cholestatic liver diseases. Typically recognized in pediatric settings, they can present across the lifespan and pose particular challenges in adults. This interactive, case-based symposium will improve clinicians' competence in recognizing, diagnosing, and managing PFIC and ALGS in adults.

From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

Supported by: Novo Nordisk
Organized by: Voxmedia LLC

Convention Center: Four Seasons Ballroom 1

MASH, the progressive, inflammatory form of MASLD, is an increasing cause of end-stage liver disease. The therapeutic landscape has transformed with FDA approvals of resmetirom and semaglutide; optimal agent selection is complex. FGF21 analogs are in clinical development. This program is designed for those who manage patients with MASH.

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

Supported by: AstraZeneca
Organized by: Physicians' Education Resource, LLC (PER)

Convention Center: Four Seasons Ballroom 2 - 3

Join the conversation at PER's hybrid CME satellite symposium! This interactive format will feature emerging clinical evidence via real patient cases and decision points, covering treatment selection and multidisciplinary strategies across the HCC and BTC continuum.

1 – 4:30 PM

Obesity Medicine Course, Parts 1 and 2: Obesity and the Liver—From Metabolic Dysfunction–Associated Steatotic Liver Disease to Cardiovascular-Kidney-Liver-Metabolic Diseases

Convention Center: Bluebird Ballroom 2ABC

This timely course provides a comprehensive overview of obesity as a multisystem disease with major implications for liver health. Using the frameworks of metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic-kidney-liver-metabolic disease (CKLM), the course integrates pathophysiology, noninvasive risk stratification, and therapeutic approaches across lifestyle, pharmacologic, and procedural interventions.

Podcast recording.

THURSDAY, NOVEMBER 5

2 – 3:30 PM

Caregiver, Family, and Rural Area Challenges

Convention Center: Mile High Ballroom 4DEF

This unique program brings together patients, caregivers, and clinicians to share stories and practical advice about living with liver disease. Caregivers discuss supporting a loved one with liver disease-the emotional ups and downs, stress, and self-care. Panelists address mental health concerns, reducing stigma, effective communication with health care practitioners, and transitioning from pediatric to adult health care.

2:30 – 3 PM

Hepatotoxicity SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Hepatotoxicity SIG.

Inside the Journals: How Independent National Monitoring Can Drive WHO Resolution Implementation on SLD

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Jeffrey V. Lazarus, PhD

2:30 – 3:30 PM

First Timers Meet-Up

Convention Center: Summit 5 and 6, The Park @ TLM, Hall D

Start your #TLM26 experience by connecting with local hepatology leaders who are excited to meet you, share insights, and help make your first meeting a success. Bring your questions, and leave with new connections and confidence for the week ahead.

From Bench to Bedside: How to Take Research Discoveries to the Clinic

Convention Center: Summit 4, The Park @ TLM, Hall D

Every day scientists make exciting discoveries that have the potential to improve human health. The path to the clinic, however, can be challenging. In this session, scientist-physician pairs give short presentations summarizing how they took their discoveries from the bench to the bedside. The scientist discusses the process of drug discovery, development, and testing.

Hepatitis C Test and Treat 2.0: Breaking Barriers and Closing Gaps

Convention Center: Summit 3, The Park @ TLM, Hall D

Join this cutting-edge program in which experts review and discuss the patient perspective of hepatitis C test and treat strategies; test and treat models of hepatitis C care across various settings; and diagnostic, treatment, and guideline advances.

3 – 3:30 PM

Inside the Journals: BEACON HCC

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Amit G. Singal, MD, MS, FAASLD

4 – 5:30 PM

Elevating Navigation in Liver Care: Open Access, Artificial Intelligence, and the Evolving Patient-Clinician Partnership

Convention Center: Mile High Ballroom 4DEF

As liver care becomes increasingly digital, expanded access to medical records, clinical notes, and artificial intelligence (AI)-supported tools is reshaping how patients understand and engage in their care. When integrated thoughtfully, these tools have the potential to improve clarity, support earlier recognition of disease patterns, and enhance patient-clinician communication. At the same time, increased transparency and patient-facing AI tools can introduce complexity.

6 – 7 PM

PRIDE Reception

Hyatt Regency, Capitol Ballroom 4

Join us for AASLD's Pride Reception, hosted by the LGBTQ+ Subcommittee. This reception offers a warm and welcoming space for LGBTQ+ members and allies to connect, build community, and celebrate the values of inclusion and belonging within hepatology. Come share experiences, forge new connections, and help strengthen the spirit of community that supports every member of our field.

6 – 8 PM

Metabolic Connections: Rethinking MASLD, MASH, and Obesity in an Evolving Management Landscape

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.
Organized by: Clinical Care Options, LLC dba Decera Clinical Education

Hyatt Regency, Centennial Ballroom E

Evidence increasingly highlights the overlapping prevalence and shared pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and other cardiometabolic conditions, yet the interconnected nature of these diseases is often underrecognized in patient care. Guideline-recommended screening for MASLD remains low among patients at increased risk, such as those with obesity, and many adults with MASLD are unaware of their condition. At the same time, rapidly evolving evidence, guidelines, and treatment options are expanding opportunities to address obesity and related conditions while creating new challenges for clinicians in providing integrated care. A clear understanding of the links among obesity, MASLD/MASH, and cardiometabolic disease, along with the role of treatments targeting weight loss in improving metabolic health, is essential for optimal patient care. Focusing on small-group, case-based discussions and real-time expert feedback, this symposium will equip healthcare professionals to consider underlying pathophysiology, apply screening and risk-stratification strategies, and translate emerging evidence into practice as they develop individualized, comprehensive care plans that support liver and overall cardiometabolic health.

7 – 7:45 PM

Diversity Reception

Hyatt Regency, Capitol Ballroom 1 - 3

Join us at the Diversity Reception hosted by AASLD's Inclusion and Diversity Committee to celebrate the rich experiences and perspectives that strengthen the Hepatology community. Connect with colleagues, share your story, and engage in meaningful conversation in a welcoming space built on connection, respect, and belonging.


By invitation only.


Ticket required.


AASLD members only.

FRIDAY, NOVEMBER 6

7 – 7:45 AM

Meet-the-Experts (MTE) #1: Acute-on-Chronic Liver Failure at the Crossroads—High-Stakes Decisions in Critical Care, Advanced Organ Support, and Palliation

Convention Center: Room 1A

Managing acute-on-chronic liver failure (ACLF) in the intensive care unit often involves navigating some of the most complex and ethically charged decisions in hepatology and critical care. Experts explore the pivotal moments when clinicians must decide whether to escalate aggressive organ support or transition toward palliative approaches.

MTE #2: New Frontiers in Targeting Alcohol Use and Liver Disease—Fibroblast Growth Factor 21 and Glucagon-like Peptide-1 Receptor Agonists

Convention Center: Room 1B

Join topic experts for this intriguing session that explores the emerging therapeutic landscape for treating alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Speakers focus specifically on fibroblast growth factor 21 (FGF21) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of AUD and ALD. Presenters also explore future translational research questions involving FGF21 and GLP-1 RAs.

MTE #3: Beyond Steroids—Managing Complex Rejection After Liver Transplantation

Convention Center: Room 1C

Learn from the experts in this practical, case-based discussion regarding the diagnosis and management of complex liver allograft rejection. Faculty focus on real-world scenarios including antibody-mediated rejection, steroid-resistant T cell-mediated rejection, plasma cell-rich rejection, and chronic rejection. Attendees participate in an informative interactive discussion and learn management pearls for challenging rejection cases.

MTE #4: The Genetic Blueprint of Metabolic Dysfunction–Associated Steatotic Liver Disease—Mapping Risk, Mechanisms, and Progression

Convention Center: Room 1D

Take advantage of this opportunity to discuss the genetic underpinnings of metabolic dysfunction-associated steatotic liver disease (MASLD) with topic experts. Faculty address and review the genetic risk and protective factors for MASLD onset, development, and progression. Presenters also highlight the role of genetic risk scores in MASLD.

MTE #5: Gene-Based Therapy in Liver Disease—Promise, Ethics, and Responsibilities

Convention Center: Room 1E

Gene therapy trials for liver diseases present unprecedented opportunities for both patients and investigators. While offering the potential for durable disease modification for patients, gene therapies also raise complex questions for investigators regarding informed consent, heightened safety monitoring requirements, equity of access, pediatric enrollment, long-term follow-up obligations, and investigator responsibility for therapies with potentially irreversible effects.

MTE #6: New Hepatitis B Virus and Hepatitis D Virus Treatments Including Drugs in Development

Convention Center: Room 1F

The recent wealth of new clinical trial data addressing the treatment of persons living with hepatitis B virus (HBV) moninfection, and HBV and hepatitis D virus (HDV) coinfection has fueled excitement among clinicians regarding the prospect of cures for HBV infection and HBV/HDV coinfection.

MTE #7: What to Do With Hepatocellular Carcinoma Screening and Surveillance in Patients With Prior Hepatitis C Virus Infection

Convention Center: Room 4A

Join experts to discuss advances in hepatocellular carcinoma (HCC) management among persons with current or prior hepatitis C virus (HCV) infection. Presenters highlight updated American Association for the Study of Liver Diseases guidelines including the optimal timing of HCV treatment and post sustained virologic response (SVR) HCC surveillance.

8 – 9 AM

Liver Fibrosis SIG Membership Meeting

Convention Center: Bluebird Ballroom 2ABC

Open to all TLM attendees. SIG members are encouraged to attend as an opportunity to connect with leadership and members.

8 – 9:30 AM

Artificial Intelligence and Machine Learning in Practice

Convention Center: Bluebird Ballroom 3ABC

Artificial Intelligence (AI) and machine learning (ML) tools are increasingly marketed for clinical use. Yet many clinicians, researchers, and health system leaders lack structured approaches to critically evaluate these models, understand their real-world implications, and plan for responsible scale.

Best of The Liver Fellow Network

Convention Center: Bluebird Ballroom 3DEF

This workshop highlights the offerings of the Liver Fellow Network (LFN) with presentations of the most impactful posts by content creators in the featured core series: Clinical Pearls, Evidence Corner, Why? Series, and Back to Basics. The session also features an inaugural presentation from the new Guidelines series. A discussion moderated by LFN fellow leads and faculty chairs follows each presentation.

Fundamentals of Liver Disease: Inpatient Hepatology Management in 2026

Convention Center: Bluebird Ballroom 1B

Presenters highlight recent advances in the management of liver diseases commonly encountered in general gastroenterology and community-based inpatient practices. Using a case-based approach, speakers address: - Variceal hemorrhage management. Speakers review advanced management of variceal hemorrhage, going beyond the basics of resuscitation and variceal band ligation.

Podcast recording.

FRIDAY, NOVEMBER 6

8 – 9:30 AM

Hepatitis B Virus Infection at All Ages and Stages

Convention Center: Mile High Ballroom 2A - 3A

Chronic hepatitis B virus (HBV) infection affects 250 million persons worldwide at all ages of life. It can be a heterogeneous disease with variable manifestations in children, immunocompromised persons, those with hepatitis D virus (HDV) coinfection, and older adults.

Hepatitis C Elimination: Where Are We Now?

Convention Center: Bluebird Ballroom 1A

This pivotal program examines and reviews the latest information regarding hepatitis C elimination, including where global and national progress has succeeded and stalled; what treatment strategies could get us back on track; and what prevention strategies are still needed.

Mutual Learning in Hepatology: Bridging Pediatric and Adult Perspectives and Experiences

Convention Center: Mile High Ballroom 2B - 3B

This unique program brings together pediatric and adult hepatologists to discuss and share knowledge and experiences with a variety of liver diseases.

Pediatric and Rare Liver Diseases: Challenges and Opportunities

Convention Center: Mile High Ballroom 4DEF

Pediatric and rare liver diseases present unique diagnostic, therapeutic, and psychosocial challenges for children and their families. Delayed diagnosis, limited treatment options, fragmented care, and inequitable access to specialty services continue to impact outcomes across the lifespan. Program presenters provide an overview of challenges and solutions, and share a view of what may be in store in the future.

Real-World, Data-Driven Strategies to Improve Outcomes in Cirrhosis and Metabolic Disease

Convention Center: Bluebird Ballroom 2DEF

Examine the complexities of translating scientific research and real-world data into actionable clinical workflows in the care of patients with cirrhosis and coexisting metabolic disease across the transplant continuum in this educational session.

9:45 – 10:15 AM

Hepatitis C SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Hepatitis C SIG.

Inside the Journals: Qualitative Methods in Chronic Liver Disease

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Donna M. Evon, PhD

9:45 – 10:45 AM

Academic Debate: Is Resmetirom or Semaglutide the Best First-Line Treatment for Metabolic Dysfunction–Associated Steatohepatitis With Stage 2–3 Fibrosis?

Convention Center: Bluebird Ballroom 1C

Explore timely topics in liver disease in a lively debate format as hepatology trainees and practicing hepatologists tackle important often controversial issues. Debaters gain skills in critical thinking, balanced argumentation, and factual examination of each issue's pros and cons. Debaters, judges, and audience members grapple with opposing scientific, societal, individual, and financial viewpoints on current clinical concerns.

Diversity Meet-Up

Convention Center: Summit 5 and 6, The Park @ TLM, Hall D

Join AASLD's Diversity, Equity, and Inclusion (DE&I) Committees for a networking Meet-Up at The Park @ TLM during The Liver Meeting (TLM). Connect with colleagues from across the liver community, expand your professional network, and engage in meaningful conversations about advancing diversity, equity, inclusion, and belonging in hepatology. All attendees interested in fostering a more inclusive community are welcome.

Electronic Health Records: Tips to Speed Up Your Workflow

Convention Center: Bluebird Ballroom 2GH

This community conversation highlights practical strategies to improve efficiency in hepatology practice by leveraging both artificial intelligence (AI) and high-impact, non-AI tools embedded within the Epic electronic health record (EHR).

Implementation of Liver Point-of-Care Ultrasonography in Clinical Practice

Convention Center: Summit 3, The Park @ TLM, Hall D

Point-of-care ultrasonography (POCUS) is considered the new stethoscope. Speakers highlight basic aspects of the use of liver POCUS in clinical hepatology. Faculty focus on practical aspects related to patient care and practice efficacy; benefits for patients and clinicians; barriers to implementation; and the optimal approach for those interested in considering incorporating liver POCUS into their clinincal practice.

Navigating Academic Career Decisions in Medicine: From Training to Thriving

Convention Center: Bluebird Ballroom 3GH

This career-focused program is intended for hepatology fellows, early-career faculty, and junior investigators in clinical, transplant, and basic/translational liver research who are navigating career transitions, academic advancement, and leadership development within academic medicine. The panel addresses key communication challenges faced by trainees, and early-career and mid-career hepatologists, including career transitions, negotiation, self-endorsement, and academic promotion.

By invitation only. *Ticket required.* *AASLD members only.*

FRIDAY, NOVEMBER 6

9:45 – 10:45 AM

Special Interest Group (SIG) Membership Meetings

Open to all TLM attendees. SIG members are encouraged to attend as an opportunity to connect with leadership and members.

- ACLF SIG, Mile High Ballroom 2B - 3B
- ALD SIG, Bluebird Ballroom 1B
- Cholestatic SIG, Bluebird Ballroom 2ABC
- Hepatotoxicity SIG, Bluebird Ballroom 3DEF
- Liver Cancer SIG, Room 403 - 404
- Liver Cell Biology SIG, Room 405 - 407
- MASLD SIG, Bluebird Ballroom 1A
- Pediatric SIG, Mile High Ballroom 2A - 3A
- Portal Hypertension SIG, Bluebird Ballroom 3ABC
- Public Health SIG, Bluebird Ballroom 2DEF

10:15 – 10:45 AM

Hepatitis B/D SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Hepatitis B/D SIG.

Inside the Journals: Telehealth Interventions in LT

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Sarah R. Lieber, MD

11 AM – NOON

Special Interest Group (SIG) Membership Meetings

Convention Center: Summit 1, The Park @ TLM, Hall D

All members of the SIG are invited to attend.

- CIDH SIG, Bluebird Ballroom 2GH
- Clinical Practice SIG, Bluebird Ballroom 2DEF

11 AM – 12:30 PM

Acute-on-Chronic Liver Failure: Year for Collaborative Research

Convention Center: Mile High Ballroom 2B - 3B

The definition and research framework for acute-on-chronic liver failure (ACLF) remain fragmented across different regions of the world. The primary objective is to bring together global experts, field leaders, and researchers to work collaboratively toward a unified understanding of ACLF.

Beyond the Transplant: Innovation, Survival, and the Patient Journey

Convention Center: Mile High Ballroom 4DEF

Developed by the Patient Advisory Group, this informative session explores the evolution of transplantation (ideal versus less-than-ideal donors) and the impact of machine perfusion on liver transplants. Presenters discuss challenges for long-term transplant survivors including models to inform. The patient perspective is shared with a discussion of mental health challenges, including hepatic encephalopathy, depression, and family discussions.

From Evidence to Practice: New Guidelines on Hepatitis Delta, Pediatric Liver Transplantation, Primary Biliary Cholangitis, and Pruritus

Convention Center: General Session, Hall A

Join this timely session that presents major new clinical guidelines and expert consensus documents that are shaping contemporary hepatology practice.

From Fellows to Faculty: Career Development for Budding Hepatologists

Convention Center: Bluebird Ballroom 2ABC

In the setting of an emerging shortage of hepatologists, this session-presented by the Liver Fellow Network-aims to demystify the hidden curriculum and equip emerging hepatologists with fundamental professional development skills that are critical yet often underemphasized during early career transitions.

From Words to Outcomes: Transforming Care for Alcohol-Associated Liver Disease, Part 1

Convention Center: Bluebird Ballroom 1B

Jointly planned by the Alcohol-Associated Liver Disease and Public Health/ Health Delivery Special Interest Groups, this 2-part symposium examines transformation of care for alcohol-associated liver disease (ALD) through the lens of health delivery and engagement to improve outcomes. Key concepts explored in part 1 of the symposium focus on communication to improve engagment, including: - Language and stigma - Trauma-informed care - Motivational interviewing - Serious illness communication.

More Than Fibrosis: The Biology and Prognostic Power of Liver Stiffness, Part 1

Convention Center:Bluebird Ballroom 3DEF

This joint educational session of the Autoimmune and Cholestatic Liver Disease and Fibrosis Special Interest Groups examines liver stiffness as a unifying concept linking fibrosis, immune-mediated injury, and clinical outcomes across autoimmune, cholestatic, and metabolic liver diseases.

Our Livers in a Polluted Environment: Mechanisms and Clinical Implications

Convention Center: Mile High Ballroom 2A - 3A

Expert clinicians and basic scientists come together to explore emerging insights into how environmental chemicals contribute to liver disease pathogenesis.



Podcast recording.

FRIDAY, NOVEMBER 6

11 AM – 12:30 PM

Personalized Management of Portal Hypertension Across the Lifespan, Part 1

Convention Center: Bluebird Ballroom 3ABC

Portal hypertension is a complex, heterogeneous condition. Its presentation, mechanisms, and clinical consequences vary widely across age groups, etiologies, and individual patient characteristics. Traditional, uniform approaches to risk stratification and management are increasingly insufficient to address this complexity, particularly as new diagnostic tools, genetic insights, and therapeutic strategies emerge.

The Metabolic Dysfunction–Associated Steatotic Liver Disease and Hepatocellular Carcinoma Continuum: Fibrosis, Inflammation, and Clinical Decision-Making, Part 1

Convention Center: Bluebird Ballroom 1A

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading driver of fibrosis progression and hepatocellular carcinoma (HCC), with implications that extend beyond the liver. This joint session traces the clinical continuum from MASLD/metabolic dysfunction-associated steatohepatitis (MASH) to liver cancer, highlighting how metabolic inflammation, fibrosis, and comorbidity shape cancer risk, prevention, and treatment.

12:30 – 1 PM

AASLD Leadership Luncheon

Convention Center: Room 403 - 404

AASLD Leadership Luncheon.

12:30 – 2 PM

Advanced Practice Providers' Networking Lunch

Supported by: Alfasigma, Ipsen, GSK, Gilead Sciences and Madrigal

Convention Center: Room 405 - 407

Breaking News: A New Era for Noninvasive Tests to Detect Liver Fibrosis & Identify Patients for Novel Therapies

Supported by: Siemens Healthineers
Organized by: Medscape Education

Convention Center: Four Seasons Ballroom 1

We're tackling a rapidly evolving landscape of MASH. With new therapies now available for non-cirrhotic MASH with significant fibrosis, accurate patient stratification is essential. Noninvasive testing (NIT) has proven to be a highly accurate and practical tool for detecting significant liver fibrosis. This engaging session highlights the urgent unmet needs in MASH management and reviews the latest clinical data on breakthrough treatments. The live exchange between experts will dive into the practical, clinical utility of NITs for accurately assessing liver fibrosis.

Patient-Centered Care: Managing Primary Biliary Cholangitis in the Clinic

Supported by: Ipsen
Organized by: Medscape Education and PBC Foundation

Convention Center: Four Seasons Ballroom 2 - 3

Unlock key insights and practical strategies in the management of primary biliary cholangitis (PBC) at this dynamic, case-based "Medscape Clinic style" symposium. Hear from expert faculty as they discuss the latest in PBC diagnosis, risk assessment, treatment selection, setting goals with patients, and other important topics. Through interactive discussions and real-world cases, you'll come away with a better understanding of comprehensive PBC management that you can apply to your own patients in the clinic. Don't miss this opportunity to advance your expertise and elevate outcomes for your patients with PBC.

Redefining Success: Individualizing HBV Care

Supported by: Aligos Therapeutics
Organized by: Clinical Care Options, LLC dba Decera Clinical Education

Convention Center: Four Seasons Ballroom 4

As emerging therapies expand the potential for functional cure in chronic hepatitis B, this endpoint may be appropriate for some patients, but not all. This symposium will explore individualized treatment goals, including durable viral suppression, partial cure, and functional cure, and how patient characteristics and preferences guide treatment decisions.

12:45 – 1:30 PM

MTE #8: Acute-on-Chronic Liver Failure in Practice—Early Recognition and Decision-Making at the Bedside

Convention Center: Room 1A

Early recognition and classification of acute-on-chronic liver failure (ACLF) remains a major challenge, often resulting in delayed care and missed critical intervention windows. As global definitions evolve, clinicians must apply these frameworks in real time-sometimes before formal criteria are met.

MTE #9: How to Start an Integrated Alcohol-Associated Liver Disease Clinic—Barriers and Successes

Convention Center: Room 1B

Faculty review the practical aspects of implementing integrated alcohol-associated liver disease (ALD) care. Topics include organizing a care team, development of a business plan, and barriers and pitfalls as presented by experts who have successfully started integrated ALD care programs.

MTE #10: How to Incorporate Artificial Intelligence in Medical Education

Convention Center: Room 1C

Artificial intelligence (AI) tools are increasingly integrated into hepatology clinical practice and training (eg, ambient scribes/note drafting in clinic, chart summarization on consult services, and AI-enabled platforms that synthesize evidence for point-of-care questions).

By invitation only. Ticket required. AASLD members only.

FRIDAY, NOVEMBER 6

12:45 – 1:30 PM

MTE #11: Women's Health and Liver Disease

Convention Center: Room 1D

Women living with liver disease often have concerns not experienced by men with liver disease. Join experts to discuss women's health among those living with liver disease. Faculty discuss and review the role of estrogens in liver disease; the impact of liver disease in the safe use of contraception and hormone replacement therapy; and pregnancy and family planning.

MTE #12: Beyond Fibrosis Staging—Integrating Hemodynamics and Noninvasive Testing for Predicting Portal Hypertension Decompensation, Recompensation, and Therapeutic Response

Convention Center: Room 1E

Risk stratification in chronic liver disease is evolving from static fibrosis staging toward dynamic prediction of cirrhosis progression, portal hypertension, and clinical decompensation. Learn from topic experts who examine how established and emerging noninvasive tools-using a physiology-driven approach-can more accurately capture the determinants of disease progression.

MTE #13: Novel Modalities for Hepatitis B–Related Hepatocellular Carcinoma Screening and Surveillance

Convention Center: Room 1F

Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains the most common complication of chronic HBV infection. Treatment with HBV antiviral therapy has been shown to reduce the risk of HCC but does not completely eliminate it. Currrent screening and surveillance strategies that require the use of abdominal ultrasound, with or without alpha-fetoprotein testing, are suboptimal. Therefore, novel approaches to HCC screening and surveillance are urgently needed in clincial practice.

MTE #14: Emerging Approaches to Managing Complex Cases of Cholestatic and Autoimmune Liver Disease in Pregnancy

Convention Center: Room 4A

Expert faculty review important considerations and updates regarding the management of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and autoimmune hepatitis (AIH) in pregnancy through case-based discussion. The PBC case highlights the approach to preconception counseling of an individual on second-line PBC therapy.

1 – 1:30 PM

Liver Cell Biology in Hepatic Diseases SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Liver Cell Biology in Hepatic Diseases SIG.

LiverTox

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Jay H. Hoofnagle, MD, FAASLD

Podcast recording.

Quiet/Prayer Room

Convention Center: Room 202

A place for quiet reflection and prayer.

1 – 2 PM

"Shunt Happens": Contemporary Approaches to Congenital Portosystemic Shunts

Convention Center: Summit 4, The Park @ TLM, Hall D

Join an expert panel who provide a comprehensive overview of congenital portosystemic shunts in children, emphasizing the underlying vascular anatomy, embryologic development, and spectrum of anatomic variants. Presenters review the natural history of these lesions and their associated clinical sequelae, including hepatic dysfunction, pulmonary vascular complications, neurocognitive effects, and implications for growth and development.

AASLD Annual Business Meeting

Convention Center: Room 403 - 404

Annual Business Meeting for AASLD members to hear accomplishments of the past year.

Emerging Liver APP Alumni Meet-Up

Convention Center: Summit 5, The Park @ TLM, Hall D

Calling all current AASLD Foundation Emerging Liver APPs and alumni! Join us on Friday, November 6, from 1 - 2 PM at Meet Up Summit 5 for an exclusive gathering to network and build meaningful connections with fellow awardees!

Emerging Liver Scholars Alumni Meet-Up

Convention Center: Summit 6, The Park @ TLM, Hall D

Attention all current Emerging Liver Scholars and alumni! Join us on Friday, November 6, from 1 - 2 PM at Meet Up Summit 6 for an exclusive gathering to network and build meaningful connections across the ELS community. Whether you're looking to catch up with familiar faces or meet this year's awardees, we'd love to see you there!

Friday Poster Presenter Presentation Hour

Convention Center: Poster Hall, Hall DE

The following poster categories will be in the Poster Hall:

- Diagnostics and Biomarkers - MASLD and MASH
- MASLD/MASH - Epidemiology and Natural History, Prevention and Outcomes
- Health Disparities/Health Equity Research
- Health Services and Public Health Research
- Acute Liver Failure and Artificial Liver Support
- Acute on Chronic Liver Failure
- Advanced Practice Providers (NP, PA, RN, PharmD, etc.)
- Inflammation and Immunobiology
- Pediatric Hepatology

FRIDAY, NOVEMBER 6

1 – 2 PM

Hepatology Board Review Question and Answer Session

Convention Center: Summit 3, The Park @ TLM, Hall D

This interactive workshop is designed to support fellows and early-career hepatologists preparing for the transplant hepatology board examination. The session combines high-yield, test-taking strategies with real-time practice using board-style questions.

SASLT (Saudi Arabia) Podcast Recording

Convention Center: Podcast Recording Studio

1 – 4 PM

Point-of-Care Liver Ultrasonography Course: Basic Skills 1

Convention Center: Mile High Ballroom 2C - 3C

This workshop introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice. Participants receive hands-on training for performing POCUS examinations of the liver.

1:30 – 2 PM

Inside the Journals: The Burden of ALD

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Luis Antonio Diaz, MD

Liver Transplantation and Surgery (LTS) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Liver Transplantation and Surgery (LTS) SIG.

2 – 3 PM

AASLD/INASL: Updates on Diagnosis and Treatment of Hepatic Encephalopathy

Convention Center: Bluebird Ballroom 2GH

Hepatic encephalopathy (HE) remains a major challenge in the management of chronic liver disease, with significant implications for patient outcomes and quality of life. Faculty explore core topics: the phenotypic spectrum of HE; how infections, sarcopenia, and gut microbiome dynamics drive recurrence; and emerging pharmacological strategies beyond traditional therapies for HE.

Pathologists Are From Mars, Hepatologists Are From Venus: Hepatic Vascular Disorders—Blocked, Budd-ed, and Baffled

Convention Center: Bluebird Ballroom 3GH

The diagnosis of hepatic vascular disorders raises several challenges for clinicians, radiologists, and pathologists. These disorders include sinusoidal/postsinusoidal etiologies like sinusoidal obstruction syndrome (SOS), Budd-Chiari syndrome, and cardiac/pericardial disease. Diagnosis of these conditions as well as the interpretation of fibrosis and nodular lesions in this setting can be challenging.

Special Interest Group (SIG) Membership Meetings

Open to all TLM attendees. SIG members are encouraged to attend as an opportunity to connect with leadership and members.

- Hepatitis B SIG, Mile High Ballroom 2A - 3A
- Hepatitis C SIG, Bluebird Ballroom 2DEF

2 – 3:30 PM

Artificial Intelligence in Hepatology Training

Convention Center: Bluebird Ballroom 2ABC

Artificial intelligence (AI) tools are increasingly integrated into hepatology clinical practice and training, such as ambient scribes and note drafting in clinic, chart summarization on consult services, and AI-enabled platforms that synthesize evidence for point-of-care questions.

From Words to Outcomes: Transforming Care for Alcohol-Associated Liver Disease, Part 2

Convention Center: Bluebird Ballroom 1B

Jointly planned by the Alcohol-Associated Liver Disease and Public Health/Health Delivery Special Interest Groups, this 2-part symposium examines transformation of care for alcohol-associated liver disease (ALD) through the lens of health delivery and engagement to improve outcomes.

Hypoxia in Liver Health and Disease

Convention Center: Mile High Ballroom 2B - 3B

Presenters in this session discuss advances in our understanding of hepatic hypoxia and its contribution to liver physiology and pathology. The concepts covered by thought leaders and content experts include an overview of hypoxia, regulation of liver zonation by hypoxia, and the central role of hypoxia in regulating the gut-liver axis. Presenters also address the role of hypoxia in hepatic conditions such as acute liver injury, liver fibrosis, steatosis, and hepatocellular carcinoma.

Liver Cancer Diagnosis and Treatment Planning: Understanding and Improving Access to Liver Tumor Boards and Multidisciplinary Care

Convention Center: Mile High Ballroom 4DEF

Many patients with liver cancer do not receive a referral to a multidisciplinary liver tumor board-especially not in a timely manner. This may result in misdiagnosis, unnecessary diagnostic testing that delays the diagnosis, and/or delayed or failure to initiate recommended treatments. Presenters explore what multidisciplinary liver tumor boards are and how they streamline the diagnosis and treatment of patients with liver cancer.

By invitation only. *Ticket required.* *AASLD members only.*

FRIDAY, NOVEMBER 6

2 – 3:30 PM

More Than Fibrosis: The Biology and Prognostic Power of Liver Stiffness, Part 2

Convention Center: Bluebird Ballroom 3DEF

This joint educational session of the Autoimmune and Cholestatic Liver Disease and Fibrosis Special Interest Groups examines liver stiffness as a unifying concept linking fibrosis, immune-mediated injury, and clinical outcomes across autoimmune, cholestatic, and metabolic liver diseases.

Personalized Management of Portal Hypertension Across the Lifespan, Part 2

Convention Center: Bluebird Ballroom 3ABC

Portal hypertension is a complex, heterogeneous condition. Its presentation, mechanisms, and clinical consequences vary widely across age groups, etiologies, and individual patient characteristics. Traditional, uniform approaches to risk stratification and management are increasingly insufficient to address this complexity, particularly as new diagnostic tools, genetic insights, and therapeutic strategies emerge.

The Metabolic Dysfunction–Associated Steatotic Liver Disease and Hepatocellular Carcinoma Continuum: Fibrosis, Inflammation, and Clinical Decision-Making, Part 2

Convention Center: Bluebird Ballroom 1A

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading driver of fibrosis progression and hepatocellular carcinoma (HCC), with implications that extend beyond the liver. This joint session traces the clinical continuum from MASLD/metabolic dysfunction-associated steatohepatitis (MASH) to liver cancer, highlighting how metabolic inflammation, fibrosis, and comorbidity shape cancer risk, prevention, and treatment.

Wait Wait...Don't DILI!

Convention Center: Bluebird Ballroom 1C

Back on the schedule as long as they'll have us, 'Wait Wait...Don't DILI!' returns, this time for its N=4. Created by the Hepatotoxicity Special Interest Group, this unique session format features 3 scientific talks, each only 5 minutes long, followed by 10 minutes of discussion. Speakers are introduced by limericks. We have audience engagement with Slido and a celebrity interview. Prizes include custom mugs. All is based (loosely) on 'Wait Wait... Don't tell me!', the NPR radio news quiz show.

4 – 5 PM

President's Welcome and President's Choice Lecture: Approaching Patients and Decision-Makers in Our Current Anti-Science World

Convention Center: General Session, Hall A

Explores strategies for effectively communicating with patients and decision-makers and addressing misinformation and declining trust in science in today's anti-science environment.

5 – 6:30 PM

Exhibit Hall Opening Reception

Supported by: Mirum Pharmaceuticals

Convention Center: Exhibit Hall DEF

Begin your experience at The Liver Meeting with an evening of mingling, refreshments, and a warm welcome from AASLD as you explore the Exhibit Hall. This casual gathering provides the opportunity to meet new colleagues and hear from industry leaders.

7 – 8 PM

Fellows' Reception

Denver Art Museum

Celebrate hepatology and connect with peers at the Fellows' Reception, a special event dedicated to our Fellows and Associate Fellows of the American Association for the Study of Liver Diseases. This reception offers a special opportunity to network with fellow leaders and nurture lasting professional relationships within the hepatology community.

7:30 – 11:30 PM

Members' Reception

Supported by: Elevar Therapeutics, Inventiva, and Mirum Pharmaceuticals

Denver Art Museum

Join us for another unforgettable evening of celebration, networking, and inspiration at the AASLD Members' Reception during TLM26. At the Denver Art Museum on Nov. 6 from 7:30-11:30 PM, mingle with passionate colleagues, interact with our leadership, and forge new, but lasting connections.

AASLD
EDUCATION

As the trusted leader in hepatology, AASLD offers education in-person and online all year long. Visit the AASLD Education Pod located in the hallway corridor to see our most up-to-date offerings and what's upcoming for 2027. *ELEVATE* your education today!

Podcast recording.

SATURDAY, NOVEMBER 7

8 – 8:30 AM

Hyman J. Zimmerman Hepatotoxicity State of the Art: Hepatotoxicity Arising From Gene Therapy

Convention Center: General Session, Hall A

Gene therapy encompasses a range of therapeutic strategies that modify or regulate genetic material (DNA or RNA) to treat or prevent disease. Despite substantial clinical advances and multiple U.S. Food and Drug Administration (FDA) approvals, hepatotoxicity has emerged as a significant toxicity across several gene therapy platforms.

8 - 9:30 AM

AASLD/ALEH: Metabolic Dysfunction–Associated Steatotic Liver Disease - Shared Challenges, Shared Solutions

Convention Center: Mile High Ballroom 2A - 3A

Metabolic dysfunction-associated steatotic liver disease (MASLD), a central subtype within the broader spectrum of steatotic liver disease (SLD), has emerged as the most prevalent cause of chronic liver disease globally. The rising burden of MASLD across North and Latin America reflects shared metabolic risk factors, including obesity, type 2 diabetes, and cardiometabolic disease, while also highlighting distinct regional challenges.

AASLD/NASPGHAN, Part 1: Immune-Mediated Pediatric Liver Disease—From Phenotype to Precision Therapy

Convention Center: Bluebird Ballroom 3DEF

The diagnosis and management of autoimmune hepatitis in children have remained largely unchanged for decades. Jointly planned by the American Association for the Study of Liver Diseases and the North American Society for PediatricGastroenterology, Hepatology, and Nutrition, this informative session highlights advances in immunophenotyping and biomarker discovery, and explores emerging approaches to the management of refractory disease, and autoimmune hepatitis in special pediatric populations.

Basic Science Workshop, Part 1: Decoding Liver Biology Through Spatial Multi-Omics—From Architecture to Disease Mechanisms

Convention Center: Bluebird Ballroom 2ABC

The spatial organization and zonation of the liver are fundamental to its functions and ability to repair and regenerate. Disruption of this spatial organization during inflammation and injury impairs hepatic function contributing to chronic liver diseases.

Career Development Workshop: Everyday Leaders—Business and Leadership Basics

Convention Center: Room 403 - 404

This workshop aims to empower early learners and faculty at all levels to build leadership and business skills for a successful career. Presenters aim to provide the audience with a toolkit for the common skills sets that hepatologists apply in everyday practice but for which no formal training is received.

From Knowledge to Dialogue: Mastering Serious Illness Communication Across the Hepatology Workforce

Convention Center: Mile High Ballroom 2B - 3B

Effective communication is a core component of hepatology care. Yet teams may struggle with complex conversations about prognosis, goals of care, and end-of-life planning. This workshop provides advanced training for clinicians across the hepatology workforce (trainees, advance practice practitioners, physicians) in communicating with adults with serious illnesses affecting the liver (decompensated cirrhosis, hepatocellular carcinoma) and their caregivers.

Hepatitis B Virus Infection and Beyond: Viral Coinfections, Metabolic Risk, and the Evolving Pathway to Hepatocellular Carcinoma

Convention Center: Mile High Ballroom 4DEF

Developed by the Patient Advisory Group, this session explores important topics affecting persons living with hepatitis B virus (HBV) infection, including:

- Hepatocellular carcinoma (HCC) surveillance
- New American Association for the Study of Liver Diseases HBV guidelines
- Emerging diseases such as hepatitis D virus and Met-HBV
- Unique challenges of treating chronic hepatitis B and coinfections
- Barriers to surveillance and treatment

Industry Research Showcase

Convention Center: Bluebird Ballroom 1B

This session features industry-sponsored preclinical and translational research spanning novel therapeutics for Alagille syndrome, PSC, alcohol use disorder, and decompensated cirrhosis, plus hepatocyte engineering advances.

Molecular Mechanisms of Alcohol-Associated Liver Disease

Bluebird Ballroom 1C

This session explores the molecular and cellular mechanisms driving alcohol-associated liver disease. Presentations examine impaired lipophagy and lysosomal damage in hepatocellular steatosis, epigenetic remodeling of immune and inflammatory pathways, and novel approaches to targeting TNF-alpha signaling without systemic cytokine blockade.

Therapeutic Strategies in MASH: Incretins, Metabolic Modulators, and Novel Approaches

Convention Center: Bluebird Ballroom 1A

This session will examine evolving therapeutic approaches for metabolic dysfunction-associated steatohepatitis, with emphasis on pharmacologic and mechanistic interventions targeting steatohepatitis, fibrosis, metabolic dysfunction, and cirrhosis. Together, these studies showcase the expanding treatment landscape for MASH across disease stages, fibrosis severity, cardiometabolic subgroups, and emerging therapeutic mechanisms.


By invitation only.


Ticket required.


AASLD members only.

SATURDAY, NOVEMBER 7

8 AM - 12:30 PM

Hepatology Associates Course, Parts 1 and 2: Clinical Updates in Hepatology, and Current Debates and Emerging Concepts in Hepatology

Convention Center: Bluebird Ballroom 2DEF

This comprehensive educational program provides a practical update on key issues in modern hepatology across the disease spectrum. Learners explore reproductive health considerations in patients with chronic liver disease, including counseling, pregnancy planning, and management considerations. The course also delivers timely updates on hepatocellular carcinoma and hepatitis B, with a focus on evolving screening, treatment, and long-term management strategies.

8 AM – 4:30 PM

Liver Care for Frontline Clinicians

Sheraton Denver: Alpine Ballroom

With approximately 41.4% or 122 million American adults predicted to have MASLD by 2050, clinicians play a critical role in early detection and prevention, and this is why AASLD created Liver Care for Frontline Clinicians: From Assessment to Intervention.

8 AM - 4:45 PM

American Association for the Study of Liver Diseases and the International Liver Transplantation Society Transplant Course, Parts 1–5

Convention Center: Bluebird Ballroom 3ABC

The 2026 Transplant Course-jointly presented by American Association for the Study of Liver Diseases and the International Liver Transplantation Society-is a premier international educational forum for transplant surgeons, hepatologists, and multidisciplinary transplant professionals.

8:30 - 9:30 AM

Clinical Plenary #1

Convention Center: General Session, Hall A

Very recent experiences of gene therapy for non-liver disorders has, in rare cases, led to several serious hepatic toxicities including liver failure. Understanding hepatic pathophysiology, monitoring and therapeutic approaches in the modern era of gene therapy is crucial.

9 AM - NOON

Point-of-Care Liver Ultrasonography Course: Basic Skills 2

Convention Center: Mile High Ballroom 2C - 3C

This workshop introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice. Participants receive hands-on training for performing POCUS examinations of the liver.

9:45 - 10:15 AM

Public Health / Health Care Delivery (PHHD) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Public Health / Health Care Delivery (PHHD) SIG.

9:45 - 10:45 AM

AASLD Foundation Rapid-Fire Research Showcase

Convention Center: Room 405 - 407

Join this informative session that features rapid-fire research presentations from investigators funded by the American Association for the Study of Liver Diseases Foundation.

AASLD/NASPGHAN, Part 2: Biliary Atresia—Emerging Diagnostic and Therapeutic Opportunities

Convention Center: Bluebird Ballroom 3DEF

Jointly planned by the American Association for the Study of Liver Diseases and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, this educational course highlights advances in understanding the disease mechanism, early diagnostic tools, possible prognostic biomarkers for biliary atresia.

Advocacy Made Simple: How Practitioners and Patients Can Drive Change

Convention Center: Summit 3, The Park @ TLM, Hall D

Public policy advocacy is a powerful tool for improving liver health outcomes. Yet many health care practitioners and patients feel they lack the time, experience, or resources to engage effectively. This interactive community conversation brings together clinicians and patient representatives to explore practical strategies for influencing policy-even with limited bandwidth.

Liver Fellow Network Alumni Meet-Up

Convention Center: Summit 5 and 6, The Park @ TLM, Hall D

Calling all current Liver Fellow Network content creators and alumni! Join us on Saturday, November 7, from 9:45 - 10:45 AM at Meet Up Summit 5 & 6 for an exclusive gathering to catch up with familiar faces and meet this year's new content creators and LFN leads.

Public Policy: Alcohol Around the Globe

Convention Center: Mile High Ballroom 2A - 3A

Inside the Journals: AASLD AGA Guideline on Management of PBC

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Therese Bittermann, MD

Podcast recording.

SATURDAY, NOVEMBER 7

9:45 - 10:45 AM

Patients and Practitioners: Seeing Eye to Eye on the Use of Artificial Intelligence and Digital Tools for Clinical Care

Convention Center: Room 403 - 404

Persons living with chronic liver disease are burdened by symptoms that negatively impact their quality of life, complications that result in frequent hospitalizations, and medications that require close monitoring and frequent titration. The holy grail of optimal hepatology care is a close patient-clinician relationship with easy access and efficient methods for medication adjustment and symptom monitoring.

Real-Life Management of Primary Sclerosing Cholangitis and Primary Sclerosing Cholangitis–Inflammatory Bowel Disease: Integrating Liver and Bowel Care

Convention Center: Bluebird Ballroom 3GH

Primary sclerosing cholangitis (PSC) remains without an approved medical therapy, leaving clinicians to navigate highly variable and often conflicting real-world practices. Many patients receive ursodiol; others receive oral vancomycin (OV), and bowel-directed therapies that are inconsistently integrated despite strong evidence that PSC is a gut-liver axis disease.

Screening for Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Population Health Perspective

Convention Center: Bluebird Ballroom 2GH

This community conversation focuses on population health strategies for screening for fibrosis among those at risk for metabolic dysfunction-associated steatotic liver disease (MASLD). Screening for fibrosis among patients with MASLD has been recommended by hepatology, gastroenterology, and endocrinology societies but uptake has been limited.

Stump the Hepatologist

Convention Center: Bluebird Ballroom 1C

The 'Stump the Hepatologist' session demonstrates the art behind the science of working through the differential diagnosis for cases. Through live interactions with the case presenters, hepatology experts work through interesting and challenging cases and speak aloud about their thought process as the case unfolds. During the process, participants witness how experts in the field, using their knowledge base, break down and narrow their differential diagnosis to solve a case.

The Liver and Immune System: The Eternal Battle in Transplant Settings

Convention Center: Summit 4, The Park @ TLM, Hall D

This community conversation explores the complex interplay between immunosuppression and the immune system in liver transplantation settings. Expert panelists discuss strategies for safe immunosuppression minimization amid rejection risks, the evolving role of immunotherapy in persons with hepatocellular carcinoma awaiting transplant, and cautious approaches to immunotherapy for de novo malignancies post liver transplant.

The Work of the US Centers for Disease Control and Prevention, Division of Viral Hepatitis (CDC DVH)

Convention Center: Mile High Ballroom 2B - 3B

The US Centers for Disease Control and Prevention, Division of Viral Hepatitis (DVH) Director Carolyn Wester discusses the ongoing work at DVH and the division's role in supporting the national hepatitis C elimination plan.

10 - 10:45 AM

Beyond Viral Suppression: Emerging Perspectives on Functional Cure in Chronic Hepatitis B

Supported by: GSK Medical Affairs

Convention Center: Exhibit Hall F, TLM Theater 1

Scientific advances are expanding the conversation around functional cure and the future of chronic hepatitis B management. Join expert faculty to review unmet needs in CHB management; gain insights on patient evaluation and monitoring; and explore emerging scientific developments in the CHB treatment landscape that may inform future clinical practice.

Evolving Approach to Second-line Treatment in PBC: A Case-based Discussion

Supported by: Ipsen

Convention Center: Exhibit Hall F, TLM Theater 2

This session will highlight evolving approaches to second-line treatment in Primary Biliary Cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.

Advancing Treatment of Hepatitis Delta Virus in the United States

Supported by Gilead who provided funding.
Gilead has had no input into the content of the materials used at this meeting/conference.

Convention Center: Exhibit Hall F, TLM Theater 3

Non-CME educational program for U.S. HCPs reviewing HDV etiology, epidemiology, disease progression, screening/diagnosis, care-cascade gaps, and a hypothetical patient case, with an overview of bulevirtide as an FDA-approved treatment option for chronic HDV in eligible adults.

10:15 – 10:45 AM

Cholestatic and Autoimmune Liver Diseases (CALD) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Cholestatic and Autoimmune Liver Diseases (CALD) SIG.

Inside the Journals: The Hepatic Sinusoid as a Regulatory Niche

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Jordi Gracia-Sancho, PhD, FAASLD

By invitation only. Ticket required. AASLD members only.

SATURDAY, NOVEMBER 7

11 – 11:30 AM

Leon Schiff State of the Art: Integrated Alcohol-Associated Liver Disease Care

Convention Center: General Session, Hall A

Highlights multidisciplinary, integrated approaches to the prevention, diagnosis, and management of alcohol-associated liver disease across the continuum of care.

11 AM – 12:30 PM

Basic Science Workshop, Part 2: Decoding Liver Biology Through Spatial Multi-Omics: From Architecture to Disease Mechanisms

Convention Center: Bluebird Ballroom 2ABC

The spatial organization and zonation of the liver are fundamental to its functions and ability to repair and regenerate. Disruption of this spatial organization during inflammation and injury impairs hepatic function contributing to chronic liver diseases.

Cholestatic Liver Disease: Lived Experience Influencing Care Pathways

Convention Center: Mile High Ballroom 4DEF

Developed by Patient Advisory Group, this session examines the importance of the patient experience within research and clinical care with a focus on cholestatic liver disease-especially primary sclerosing cholangitis (PSC). Session themes include issues of delayed diagnosis, fragmented care, unmet symptom burdens, and ways to improve the patient experience through better care coordination.

Functional Cure and Novel Therapeutics in Chronic Hepatitis B

Convention Center: Bluebird Ballroom 1C

This session reviews progress toward functional cure in chronic hepatitis B, featuring phase 2 - 3 data on bepirovirsen, siRNA therapy, and immune correlates of HBsAg decline.

MASH: Diagnosis and Treatment Response Monitoring

Convention Center: Bluebird Ballroom 1A

This session reviews non-invasive diagnostic and monitoring tools for MASH, including novel imaging, cfDNA methylation, and composite scores for identifying fibrosis and disease progression.

Mechanisms of Cholestatic Injury and Emerging Therapeutic Strategies

Convention Center: Bluebird Ballroom 3DEF

This session explores the cellular and molecular drivers of cholestatic liver disease and emerging therapeutic strategies utilizing biliary gene therapy. Presentations examine the impact of impairments in biliary transport and signaling in promoting cholestatic injury, inflammation, and fibrosis.

Precision Hepatology in Children: Novel Therapies, Biomarkers, and Clinical Outcomes

Convention Center: Mile High Ballroom 2A - 3A

This session highlights emerging advances in pediatric hepatology, spanning gene-editing therapies, cancer biology, immune-mediated liver injury, transplant-related complications, and innovative biomarker approaches. Presentations showcase translational research and clinical studies that are advancing precision diagnosis, prognostication, and treatment of pediatric liver diseases.

Redefining Care for Acute-on-Chronic Liver Failure: Critical Illness, Organ Failures, and Global Consensus

Convention Center: Bluebird Ballroom 1B

Acute-on-chronic liver failure (ACLF) represents one of the most challenging syndromes in hepatology and critical care, characterized by rapid deterioration, multiorgan failure, and high short-term mortality. This symposium explores cutting-edge strategies for managing critically-ill ACLF patients, standardizing organ failures, and translating global consensus into clinical practice.

Viral Hepatitis Across the Spectrum From Preconception and to Adulthood: Closing Gaps in Hepatitis B and Hepatitis C Prevention and Care, Part 1

Convention Center: Mile High Ballroom 2B - 3B

Jointly presented by the Hepatitis C and Hepatitis B/Delta Special Interest Groups, the Women's Initiative Committee, and the LGBTQ Subcommittee, this timely and unique 2-part program focuses on updates and approaches to hepatitis B and hepatitis C prevention and care across the lifespan-from preconception to adulthood.

11:30 AM - 12:30 PM

Clinical Plenary #2

Convention Center: General Session, Hall A

Alcohol is a major contributor to liver disease, yet diagnostic plans and treatment approaches are not standard around the globe. This SOA lecture is aimed to explore a multidisciplinary appraoch to evaluation and treatment.

12:30 - 1PM

Advancing Management of Chronic Hepatitis B

Supported by: GlaxoSmithKline, LLC

Convention Center: Exhibit Hall F, TLM Theater 1

Join us as we explore the hanging chronic hepatitis B landscape, with a focus on how emerging approaches to disease evaluation can optimize patient outcomes. This session will examine evolving concepts in comprehensive assessment that may influence testing and treatment decisions.

Podcast recording.

SATURDAY, NOVEMBER 7

12:30 - 1PM

Pediatric Cholestasis: From Diagnosis to Long-Term Care

Supported by: Ipsen

Convention Center: Exhibit Hall F, TLM Theater 2

Join Dr Binita Kamath and Dr Cara Mack on a journey from diagnosis to long-term management in paediatric cholestatic liver diseases. This session will explore early diagnosis, nutritional support, multidisciplinary care, prognostic biomarkers, and strategies for patient management.

12:30 - 2 PM

AASLD Past Presidents' Luncheon

Convention Center: Room 403 - 404

Advanced Practice Providers' Luncheon

Supported by: Alfasigma, Ipsen, GSK, Gilead Sciences and Madrigal

Convention Center: Room 405 - 407

Breaking News in Primary Sclerosing Cholangitis: Bridging Gaps in Care

Supported by: Mirum Pharmaceuticals
Organized by: Medscape Education

Convention Center: Four Seasons Ballroom 1

Primary sclerosing cholangitis (PSC) is a rare, progressive chronic liver disease, often associated with inflammatory bowel disease, that can lead to severe liver damage, cirrhosis, and liver failure if left untreated. This engaging, newsroom-style live symposium will feature expert faculty who will discuss the latest clinical evidence and best practices for diagnosing and managing PSC and its related complications. This dynamic event will feature a professional host, a patient testimonial, and plenty of time to interact with and ask questions of the faculty, who are leaders in the field. Attendees will come away with an in-depth understanding of PSC diagnosis and management, including the latest information on emerging therapies in clinical trials. So, join us for Breaking News in PSC and learn from the best!

Paving the Way to Functional Cure for Hepatitis B

Supported by: GSK
Organized by: Prime Education, LLC

Convention Center: Four Seasons Ballroom 2 - 3

With a functional hep B cure on the horizon, providers must prepare for changing therapeutic guidelines. Join Hepatitis B Foundation Experts Drs. Su Wang, Mark Sulkowski, and Yasmin Ibrahim in person or via livestream on Nov 7th for an interactive symposium on the latest hep B treatment updates.

Where Liver Meets Lung: Coordinating Modern AATD Care

Supported by: Takeda Pharmaceuticals U.S.A., Inc.
Organized by: Answers in CME

Convention Center: Four Seasons Ballroom 4

Join leading alpha-1 antitrypsin deficiency (AATD) experts while attending The Liver Meeting® 2026! This activity will equip clinicians with tools to improve care for patients with AATD-associated liver disease. Learn about diagnosis and the clinical profiles of emerging therapies. Gain insight on coordinating care and then join the live Q&A!

12:45 – 1:30 PM

Navigating the Confluence of Metabolic Dysfunction, Alcohol Use, and Advanced Liver Disease

Supported by: Altimmune

Convention Center: Exhibit Hall F, TLM Theater 3

Through interactive expert discussion, Drs. Noureddin, Loomba, and Mellinger will explore the advanced liver disease continuum and prognostic importance of fibrosis, review metabolic drivers and the role of alcohol in advanced liver disease progression, and highlight patient-centered approaches to integrated AUD and ALD care.

MTE #15: Ileal Bile Acid Transporter Inhibitors for Cholestatic Liver Disease—Therapeutic Promise for Symptoms and Disease Modification?

Convention Center: Room 1A

Ileal bile acid transporter (IBAT) inhibitors have emerged as a novel and increasingly relevant therapeutic class in the management of cholestatic liver diseases. Initially developed to address cholestatic pruritus through interruption of enterohepatic bile acid circulation, these agents have demonstrated meaningful symptomatic benefit across multiple cholestatic conditions.

MTE #16: Hidden in the Chart—Leveraging the Electronic Health Records to Detect Fibrotic Metabolic Dysfunction–Associated Steatohepatitis

Convention Center: Room 1B

Early identification of persons at risk for fibrotic metabolic dysfunction-associated steatohepatitis (MASH) remains a major gap in care despite the availability of validated noninvasive tools. Presenters examine how electronic health record (EHR)-enabled strategies can be used to systematically identify, risk stratify, and triage patients with suspected MASH in real-world clinical settings.

By invitation only. Ticket required. AASLD members only.

SATURDAY, NOVEMBER 7

12:45 – 1:30 PM

MTE #17: Too Sick or Too Well? Managing the Transplant Waiting List and Wait List Mortality Metrics

Convention Center: Room 1C

United Network for Organ Sharing (UNOS) performance metrics-including wait list mortality rate ratio and offer acceptance rate ratio-are reshaping how liver transplant programs manage access and equity while optimizing performance. Join expert faculty to discuss approaches to optimizing these pretransplant metrics through risk stratification, transplant readiness workflows, and thoughtful timing of listing and delistings.

MTE #18: Strategies for Implementing Telehealth in Hepatology Practice

Convention Center: Room 1D

This timely expert session provides attendees opportunities to share their experiences and challenges regarding the implementation of telehealth in their hepatology practices. Faculty review a range of topics including: updated 2026 national policies around telehealth; evidence for implementing telehealth (eg, viral hepatitis, cirrhosis, metabolic dysfunction-associated steatotic liver disease, liver transplant); and existing models and toolkits.

MTE #19: Optimizing Incretin Therapy in Women—Challenges and Opportunities

Convention Center: Room 1E

Join us for an engaging session dedicated to exploring the emerging role of incretin therapy in women with liver disease. Led by specialists in hepatology and metabolic syndrome, this discussion synthesizes the latest evidence, clinical considerations, and gender-specific factors that influence the use of incretin-based treatments. Faculty present valuable insights into how these therapies can positively affect liver health, metabolic profiles, and overall outcomes among women.

MTE #20: Congenital Portosystemic Shunts—Diagnosis and Management

Convention Center: Room 1F

Congenital portosystemic shunts (CPSSs) are an underdiagnosed vascular malformation causing portomesenteric blood to partially or completely bypass the liver. These shunts are associated with a wide spectrum of clinical manifestations, some of which are life threatening such as portopulmonary hypertension and liver malignancies. Additionally, persons with CPSS may present with renal, endocrine, or neurologic signs and symptoms. Diagnostic delay is common owing to the nonspecific presentation.

MTE #21: Porto-Sinusoidal Vascular Disorder

Convention Center: Room 4A

Porto-sinusoidal vascular disorder (PSVD) has recently undergone a major conceptual shift with changes in both its name and diagnostic definition, accompanied by the development of a new diagnostic score. Despite these advances, PSVD remains a frequently underdiagnosed and misdiagnosed condition with limited awareness across clinical settings.

1 – 1:30 PM

Inside the Journals: Robotic LT

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Adeel S. Khan, MD, MPH, FACS

1 – 2 PM

Leveraging Electronic Health Record–Based, Real-World Data to Advance Hepatology and Liver Transplant Research and Clinical Care

Convention Center: Summit 4, The Park @ TLM, Hall D

Electronic health record (EHR)-based, real-world data are increasingly used in clinical research for hepatology and liver transplantation. Analysis of these data have the potential to shape quality improvement, clinical trials, and regulatory decision-making.

Lifestyle and Therapeutic Interventions for Metabolic Dysfunction–Associated Steatotic Liver Disease: An Overview and Update Spanning Pediatric and Adult Populations

Convention Center: Summit 3, The Park @ TLM, Hall D

Topic experts provide a review and discussion of lifestyle and therapeutic interventions for adult and pediatric patients with metabolic dysfunction-associated steatotic liver disease (MASLD) to avoid hepatic fibrosis progression. Presenters discuss the effectiveness of these interventions in isolation and in combination.

Liver Fellow Network Podcast Recording (LiverTalks)

Convention Center: Podcast Recording Studio

Saturday Poster Presenter Presentation Hour

Convention Center: Poster Hall, Hall DE

The following poster categories will be in the Poster Hall:

- Alcohol-Associated Liver Diseases: Clinical and Experimental
- MASLD/MASH - Experimental: Clinical
- MASLD/MASH - Therapeutics: Approved/available agents
- MASLD/MASH - Therapeutics: New Agents - MASLD and MASH
- MASLD/MASH - Treatment: Non-pharmacologic
- Hepatotoxicity
- Hepatitis C
- Liver Fibrogenesis and Non-Parenchymal Cell Biology
- Hepatitis - Other Infections

Podcast recording.

SATURDAY, NOVEMBER 7

1:30 – 2 PM

Understanding Unexplained Cholestasis: Connecting Genetic Insights to Clinical Care With a Real Patient Story

Supported by: Mirum Pharmaceuticals

Convention Center: Exhibit Hall F, TLM Theater 1

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders associated with the accumulation of toxic bile acids and progressive liver injury. In this presentation, hear an adult patient share their experience living with PFIC, while Dr. Saab reviews the signs/symptoms, the role of genetic testing in diagnosis, and treatment considerations for adults with PFIC.

The Evolving Treatment Landscape for Adults with MASH: Results from a Phase 3 Trial

Supported by: Novo Nordisk, Inc.

Convention Center: Exhibit Hall F, TLM Theater 2

Join us for a focused look at clinical data from a phase 3 trial, detailing the 72-week efficacy and safety of a treatment for adults with noncirrhotic MASH and moderate to advanced fibrosis. The session will outline how these results may support care for appropriate patients with this chronic liver disease.

Inside the Journals: AASLD EXPO on Evaluation and Management of Pruritus in Genetic Cholestatic Syndromes

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Bernadette E. Vitola, MD, MPH

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG.

2 – 2:30 PM

Hans Popper State of the Art: Modern Technologies in Spatial Omics

Convention Center: General Session, Hall A

This lecture will examine how modern spatial omics technologies are transforming liver research by enabling high-resolution mapping of the cellular and molecular architecture of healthy and diseased liver tissue. It will highlight recent advances in spatial transcriptomics, high-plex imaging, and multimodal profiling, with a focus on applications in primary sclerosing cholangitis (PSC), liver fibrosis, cirrhosis, and hepatocellular carcinoma.

2 – 3:30 PM

ACLF EndPoint: Results of the Multi-Society ACLF Harmonization

Convention Center: Bluebird Ballroom 1C

Health Equity in Transplant and Advanced Liver Disease

Convention Center: Bluebird Ballroom 3DEF

This session presents current research on health equity and disparities in liver transplantation and advanced liver disease in the United States. There is a significant focus on variable access to lifesaving treatments for end stage liver disease, with variability based on geographic, insurance-based, and racial or ethnic factors.

Integrating Noninvasive Diagnostics, Precision Risk Prediction, and Novel Therapeutic Strategies in Chronic Liver Disease

Convention Center: Bluebird Ballroom 1B

The management of chronic liver disease is rapidly evolving from static assessments of fibrosis toward a more comprehensive, precision-based approach that incorporates advanced imaging, noninvasive biomarkers, and emerging therapeutic strategies.

Metabolic Dysfunction–Associated Steatotic Liver Disease and Glucagon-like Peptide-1 Drugs: What Patients Want to Know

Convention Center: Mile High Ballroom 4DEF

Glucagon-like peptide-1 (GLP-1) drugs-including both GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] receptor agonists-have become ubiquitous in the public arena. These drugs represent some of the most promising treatment options for persons with metabolic dysfunction-associated steatohepatitis (MASH) because they treat the underlying comorbidities (obesity and diabetes) as well as MASH. Additionally, they have proven cardiovascular benefits.

Point-of-Care Liver Ultrasonography Course, Advanced Skills 1

Convention Center: Mile High Ballroom 2C - 3C

This workshop provides advanced training for use of liver point-of-care ultrasonography (POCUS). It is intended for professionals who have previously completed the Basic Skills Liver POCUS course at The Liver Meeting or Digestive Disease Week. The workshop includes a theoretical portion focusing on assessment of inpatient liver findings using POCUS, liver elastography, and advice on implementing liver POCUS in clinical practice.

Results of the Multi-Society ACLF Harmonization

Convention Center: Mile High Ballroom 2A - 3A

Disseminate the Harmonization efforts that have resulted in key statements that will inform clinical practice and clinical trial design.

By invitation only. Ticket required. AASLD members only.

SATURDAY, NOVEMBER 7

2 – 3:30 PM

Right Test, Right Time: Integrating Imaging, Tissue, and Specialized Biomarkers in Hepatology

Convention Center: Bluebird Ballroom 2DEF

Accurate liver diagnosis demands confident imaging interpretation, selective biopsy use, and smart application of specialized tests. This case-based session delivers practical skills in 3 areas: (1) radiology for nonradiologists; (2) biopsy in the era of noninvasive tests; and (3) uncommon diagnostics. Attendees gain actionable checklists, algorithms, and strategies for immediate clinical application.

The Editors Cut: Clinical Studies

Convention Center: Bluebird Ballroom 1A

Join this critical discussion of the most notable and influential clinical research papers published in the journal HEPATOLOGY in the past year by a team of associate editors from the journal. HEPATOLOGY associate editors Yujin Hoshida, Jennifer Lai, and Manal Abdelmalek appraise the most cutting-edge, game changing clinical science research advances.

Transforming Pediatric Cholestatic Liver Disease: New Insights into Biliary Atresia and Genetic Cholangiopathies

Convention Center: Bluebird Ballroom 2ABC

This session presents genetic and mechanistic insights into biliary atresia and pediatric cholangiopathies, alongside emerging therapies and outcomes following Kasai portoenterostomy.

Viral Hepatitis Across the Spectrum From Preconception and to Adulthood: Closing Gaps in Hepatitis B and Hepatitis C Prevention and Care, Part 2

Convention Center: Mile High Ballroom 2B - 3B

Jointly presented by the Hepatitis C and Hepatitis B/Delta Special Interest Groups, the Women's Initiative Committee, and the LGBTQ Subcommittee, this timely and unique 2-part program focuses on updates and approaches to hepatitis B and hepatitis C prevention and care across the lifespan-from preconception to adulthood.

2:30 - 3:30 PM

Basic Science Plenary

Convention Center: General Session, Hall A

Presidential Basic Science Plenary Abstracts that highlight advances and discoveries for liver biology and pathobiology rooted in pre-clinical and translational research.

3:30 – 4:15 PM

Clinical Insights Into a First-in-Class Treatment for Primary Biliary Cholangitis (PBC)

Supported by: Gilead Sciences, Inc.

Convention Center: Exhibit Hall F, TLM Theater 2

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

The Pancreas, the Bile Duct, and Beyond: Management With the First FDA-Approved Treatment for IgG4-Related Disease

Supported by: Amgen

Convention Center: Exhibit Hall F, TLM Theater 3

Highlight expert perspectives on diagnosing IgG4-RD and its manifestations, including type 1 AIP and IgG4-related sclerosing cholangitis. Review Importance of assessing patients with IgG4-RD for extra-GI manifestations and highlight clinical trial data.

Rethinking MASH: Integrating Systemic Risk with Liver-Centered Disease Mechanisms

Supported by: Madrigal

Convention Center: Exhibit Hall F, TLM Theater 1

MASLD arises within systemic metabolic dysfunction, but what determines progression to MASH and fibrosis within the liver? This program examines how hepatic metabolic adaptation can become maladaptive under persistent stress, triggering cellular injury, inflammatory signaling, and fibrogenesis that drive progressive liver disease.

3:45 - 4:15 PM

Clinical Informatics & Digital Health (CIDH) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Clinical Informatics & Digital Health (CIDH) SIG.

3:45 - 4:45 PM

AASLD/CHESS: Advances in the Screening, Diagnosis and Treatment of Liver Fibrosis

Convention Center: Mile High Ballroom 2A - 3A

Liver fibrosis is a key determinant of liver-related morbidity and mortality across a broad spectrum of chronic liver diseases, including MASLD/MASH, viral hepatitis, and alcohol-related liver disease. Recent years have witnessed remarkable progress in non-invasive assessment tools, including serum biomarkers, imaging technologies, artificial intelligence-assisted risk stratification, and multi-omics approaches, which are transforming the screening, diagnosis and monitoring of liver fibrosis.

Podcast recording.

SATURDAY, NOVEMBER 7

3:45 - 4:45 PM

AASLD/SOLDA: A Regional Comparison of Liver Cancer in North Africa and Sub-saharan Africa

Convention Center: Bluebird Ballroom 2GH

Liver cancer is one of the most lethal cancers in Africa. Yet its burden and drivers vary widely across different regions. This series of presentations explores key differences between North Africa and Sub-Saharan Africa, focusing on contrasting patterns of incidence, risk factors, and outcomes.

Advancing Equity in Hepatology: Research and Community Partnerships

Convention Center: Room 403 - 404

Diversity, equity, and inclusion (DEI) efforts in hepatology face growing pressure from shifting political, regulatory, and funding environments, despite ongoing disparities. This session outlines a 3-part practical playbook. Presenters begin by reviewing strategic design of clinical trials to improve inclusivity. Next, faculty review best practices in sustainable collaboration with community organizations and patient advocacy partners, despite intensifying funding challenges.

ALEH Meet-Up

Convention Center: Summit 5, The Park @ TLM, Hall D

Members of the Latin American Association for the Study of the Liver (ALEH) are invited to an exclusive networking gathering at The Park @ TLM during this year's The Liver Meeting (TLM). Connect with fellow ALEH members and society leadership, strengthen professional relationships, and engage in conversations about topics and opportunities relevant to the Latin American liver community. We look forward to welcoming you to this special networking event.

Hepatology Associates SIG Membership Meeting

Convention Center: Bluebird Ballroom 2DEF

All members of the Hepatology Associates SIG are invited to attend this meeting.

Liver Health Advocacy to Improve the Lives of Persons With Liver Disease

Convention Center: Mile High Ballroom 2B - 3B

The American Association for the Study of Liver Diseases Public Policy Committee explores challenges for liver health professionals within the health policy landscape, with particular emphasis on physician reimbursement, National Institutes of Health funding, vaccines and hepatitis B, and the Cure Hepatitis C Act of 2025.

Pediatric Metabolic Dysfunction–Associated Steatotic Liver Disease Pharmacotherapy: Pathways to Regulatory Approval

Convention Center: Bluebird Ballroom 3GH

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in children. Yet no pharmacotherapies are currently approved for pediatric use. Despite rapid advances in adult MASLD/metabolic dysfunction-associated steatohepatitis (MASH) drug development, translation/extrapolation to pediatric populations remains limited due to biologic differences, ethical considerations, feasibility challenges, and regulatory uncertainty.

The Liver Fellow Network: Ask Me Anything

Convention Center: Room 405 - 407

The popular Liver Fellow Network's 'Ask Me Anything' session returns again to The Liver Meeting as both a networking and advising session. Using a small-group discussion format, faculty and liver fellows address topics regarding pathways to hepatology training, research opportunities, networking, finding a training position or job, and other questions attendees may have about entering the field of hepatology.

The Weight of Hepatotoxicity: Liver Injury in the Age of Weight Loss Therapies

Convention Center: Summit 4, The Park @ TLM, Hall D

The exponential global rise in type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH) has driven the pursuit of increasingly effective therapies. Glucagon-like peptide-1 receptor agonsits (GLP-1 RAs) have revolutionaled the management of these diseases but are not without risk. While rare, liver injury potentially associated with GLP-1 RA use is becoming more widely known; it is an increasing concern for drug developers as well as clinicians and their patients.

Top Questions in Alcohol-Associated Liver Disease: A Community Conversation on Glucagon-like Peptide-1 Receptor Agonists, Sex, and Integrated Care

Convention Center: Summit 3, The Park @ TLM, Hall D

Alcohol-associated liver disease (ALD) is evolving faster than our clinical paradigms. Women are developing severe ALD at unprecedented rates despite lower alcohol consumption levels. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer tantalizing dual benefits for cravings and steatosis. Traditional screening tools may miss high-functioning patients with metabolic risk.

4 - 5:30 PM

Supplements and Liver Safety: Patient, Caregiver, and Clinician Perspectives on Drug-Induced Liver Injury

Convention Center: Mile High Ballroom 4DEF

Join this informative session that focuses on the use of dietary supplements, herbal products, and over-the-counter remedies and their impact on liver health with particular attention on drug-induced liver injury (DILI).

By invitation only. Ticket required. AASLD members only.

SATURDAY, NOVEMBER 7

4:15 – 4:45 PM

Liver Cancer SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Liver Cancer SIG.

5 - 6:30 PM

Acute on Chronic Liver Failure

Convention Center: Bluebird Ballroom 1C

This session presents new data on predicting and managing acute-on-chronic liver failure (ACLF), covering updated diagnostic criteria, mortality risk in critically ill cirrhotic patients, and management of variceal bleeding and bloodstream infections in this population.

Advances in Primary Biliary Cholangitis: Real-World Therapeutics, Biomarkers, and Patient-Centered Outcomes

Convention Center: Bluebird Ballroom 1B

This session reviews real-world and trial data on PBC therapeutics - including elafibranor, seladelpar, and linerixibat - alongside emerging biomarkers and digital tools for tracking pruritus and disease activity.

AGA/ASGE Update: The Endo-Hepatology Frontier

Convention Center: Bluebird Ballroom 2DEF

This update, planned in partnership with the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, provides the hepatology specialist with guidance on endoscopic innovations and challenges in managing patients with liver diseases.

Enhancing Equity and Inclusion in Alcohol-Associated Liver Disease

Convention Center: Mile High Ballroom 2B - 3B

This informative symposium examines the care of patients with alcohol-associated liver disease (ALD) from an equity and inclusion perspective. Key topics include: equity in the transplant candidate selection process; socioeconomic factors that limit access to care among those with alcohol use disorder (AUD); and reducing the stigma associated with ALD and AUD.

Frailty and Metabolic Health in Transplant Candidates

Convention Center: Bluebird Ballroom 3ABC

This session explores the interplay between frailty, metabolic health, and long-term outcomes across the liver transplant continuum. Presentations characterize frailty and cardiovascular-kidney-metabolic risk from candidacy through post-transplant recovery, and examine emerging therapeutic strategies-including GLP-1 receptor agonists-to improve survival and reduce cardiometabolic complications.

Global Symposium: Hepatitis B and Hepatitis D—Clinical Advances Across Regions

Convention Center: Mile High Ballroom 2A - 3A

This cutting-edge session focuses on current and upcoming treatments for hepatitis B and hepatitis D. Presenters also discuss important updates from recent viral hepatitis guidelines across the world regarding the management of hepatitis B, and provide insight into global pediatric issues related to hepatitis B and hepatitis D.

Inflammation and Immunobiology

Convention Center: Bluebird Ballroom 3DEF

This session presents mechanistic studies of hepatic immune regulation, covering macrophage polarization, T cell responses in transplantation and cirrhosis, and circadian regulation of ischemia-reperfusion injury.

HONOR THE PAST,
SUPPORT THE FUTURE

VISIT THE WALK OF HONOR LOCATED OUTSIDE HALL A/ GENERAL SESSION OF THE CONVENTION CENTER.

Podcast recording.

SATURDAY, NOVEMBER 7

EXHIBIT HALL HOURS: 9:30 AM – 5 PM

5 - 6:30 PM

MASH: Epidemiology, Natural History, and Outcomes

Convention Center: Bluebird Ballroom 1A

This session presents population-level data on MASLD prevalence, fibrosis progression, and outcomes, including AI-based analyses of NHANES data and community screening cohorts.

The Editors Cut: Basic and Translational Research Advances

Convention Center: Bluebird Ballroom 2ABC

Join this critical discussion of the most notable and influential basic and translational research papers published in the journal HEPATOLOGY in the past year by a team of associate editors from the journal. HEPATOLOGY associate editors appraise the most cutting-edge, game changing basic and translational research advances.

5:30 – 6:30 PM

Liver Trivia

Convention Center: Room 405 - 407

Come join friends and colleagues for the 2nd Annual Liver Meeting Liver Trivia Night. Enjoy a fun way to test your knowledge about liver disease, the American Association for the Study of Liver Diseases (AASLD), and the host city of Denver, Colorado. Take advantage of the opportunity for you and your team to compete for special, limited-edition AASLD prizes.

5:45 – 6:45 PM

Hepatology Associates' Reception

Supported by: GSK, Gilead Sciences, Madrigal, Mirum Pharmaceuticals and Novo Nordisk

Convention Center: Hepatology Associates Lounge, Room 302

This exclusive event for hepatology associates (APPs, RNs, PharmD) offers a unique networking opportunity to share stories, insights, and build meaningful connections.

Open to all Hepatology Associate Attendees.

7:30 - 9 PM

Awards & Honors Gala

Convention Center: General Session, Hall A

Join us for an inspiring evening as we celebrate the individuals whose vision, leadership, scientific discoveries, and service continue to elevate the field of hepatology. The Awards & Honors Gala at TLM honors the achievements that are advancing liver health, shaping the future of care, and inspiring the next generation of leaders. Together, we'll recognize the people who are elevating the field and our community to new heights.

AASLD PUBLICATIONS

AASLD journals feature the latest scientific research, practice guidelines, and more in hepatology and liver disease. Stop by the AASLD Publications Pod to explore the latest in hepatology publishing and learn how to submit your research to an AASLD journal.

HEPATOLOGY

As AASLD's flagship journal, *HEPATOLOGY* congratulates the editorial team and leading experts, reviewers, and authors who are contributing to its *ELEVATED* impact. Visit the AASLD Publications pod to see how you can make your mark in hepatology today.



By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

7 - 7:45 AM

MTE #22: Navigating Metabolic Dysfunction–Associated Steatotic Liver Disease in Autoimmune Liver Disease—Diagnostic Dilemmas

Convention Center: Room 1A

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now so prevalent that coexistence with autoimmune liver diseases-including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC)-has become a frequent real-world scenario. This comorbid overlap creates diagnostic uncertainty and introduces management tradeoffs.

MTE #23: Talking Through the Tough Times—Strategies for Patient-Centered Liver Care

Convention Center: Room 1B

Difficult conversations are an inevitable part of hepatology practice-whether discussing prognosis, disease progression, goals of care, or transplant candidacy. These discussions can be emotionally charged and complex, requiring both clinical expertise and communication finesse. Join hepatology leaders who share practical frameworks, real-world strategies, and tips for fostering trust and clarity during these critical conversations.

MTE #24: Gene Therapies and Hepatotoxicity

Convention Center: Room 1C

Multiple gene therapies have been approved in recent years by the US Food and Drug Administration (FDA) for a variety of inherited disorders, including: - Duchenne muscular dystrophy (delandistrogene moxeparvovec-rokl, 2023) - Hemophilia A (valoctocogene roxaparvovec-rvox, 2023) - Hemophilia B (etranacogene dezaparvovec-drlb, 2022; fidanacogene elaparvovec-dzkt, 2024) - Spinal muscular atrophy (onasemnogene abeparvovec-brve, 2025) - Sickle cell disease (exagamglogene autotemcel, 2023).

MTE #25: Next Generation Multidisciplinary Liver Tumor Boards for Hepatobiliary Malignancies

Convention Center: Room 1D

Multidiciplinary tumor boards (MDTBs) are pivotal for liver cancer treatment, especially given the significant transformation in the hepatocellular carcinoma (HCC) treatment paradigm in recent years. Perons with HCC are often faced with competing mortalities-advanced liver disease and advanced cancer-neccessitating treatment options grounded in preserving liver function and quality of life.

MTE #26: Virtual Liver and Digital Twins in Liver Disease Research

Convention Center: Room 1E

Join experts for this cutting-edge session that focuses on use of systems biology and artificial intelligence tools (eg, virtual liver and digital twins) in liver disease research. Discussion topics include: how to build an omics-based liver; how to represent central physiologic functions under normal and pathologic conditions; key parameters that influence modeling; and use of virtual livers to predict clinical outcomes.

MTE #27: Human-Derived Models for the Study of Liver Diseases

Convention Center: Room 1F

This expert program showcases the latest developments in human models of liver diseases. In alignment with the US National Institutes of Health initiative to expand innovative, human-based science efforts, speakers highlight current nonanimal models such as organoids and precision cut tissue slices. Presenters discuss how to obtain and implement these nonanimal models; approaches to model liver diseases with them; and the appropriate applications.

MTE #28: Spontaneous Bacterial Peritonitis

Convention Center: Room 4A

Primary and secondary prophylaxis for spontaneous bacterial peritonitis (SBP) has been a cornerstone of cirrhosis management for decades, informed by early studies suggesting a survival benefit and reduced infectious complications. As a result, long-term antibiotic prophylaxis has become routine practice for many persons with advanced liver disease. Emerging evidence, however, is challenging this paradigm.

7 – 8 AM

Early Career Coffee & Connections hosted by the Liver Fellow Network

Convention Center: Room 405 - 407

Early Career Coffee & Connections hosted by the Liver Fellow Network offers early career professionals an opportunity to network over a light breakfast on Sunday morning. Connect with peers and leaders from the Liver Fellow Network, exchange insights, and build relationships that can support your growth in hepatology.

8 - 9 AM

Advancing Risk Stratification in MASLD and MASH: Biomarkers, Machine Learning, and Noninvasive Tools

Convention Center: Bluebird Ballroom 1A

This session will highlight emerging approaches to identifying patients with steatotic liver disease who are at greatest risk for advanced liver disease and adverse outcomes. Presentations will explore the role of lipid biomarkers, body phenotype, alcohol exposure assessment, noninvasive diagnostic criteria, and adaptive machine-learning strategies. Together, these studies underscore the evolving role of precision risk stratification in MASLD, MASH cirrhosis, and clinical trial prescreening.

Basic Mechanisms of MASH Progression

Convention Center: Bluebird Ballroom 1B

This session explores emerging mechanisms that govern the development and progression of metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Presentations will examine how hepatocyte metabolic programs, macrophage efferocytosis, bile acid signaling, natural killer cell dysfunction, aging-related ferroptosis, and fibrosis-associated cellular states contribute to liver injury and fibrogenesis.

Podcast recording.

SUNDAY, NOVEMBER 8

EXHIBIT HALL HOURS: 9:30 AM – 5 PM

8 - 9 AM

Bioengineered Liver Support, Novel Therapeutics, and Predictive Modeling in Acute Liver Failure

Convention Center: Mile High Ballroom 2A - 3A

This abstract session presents recent advances in the understanding and management of acute liver failure and acute-on-chronic liver failure. Topics include extracorporeal and bioengineered liver support devices, plasma exchange practices, novel molecular and cellular therapies, and the application of data-driven methods to guide treatment and predict outcomes.

Chronic Hepatitis B: Epidemiology, Prevention and Risk Stratification

Convention Center: Bluebird Ballroom 1C

This session covers the changing epidemiology of chronic hepatitis B, including HCC risk stratification, vaccine-derived immunity trends, screening in high-burden settings, and refugee population data.

Emerging Mechanisms and Therapeutic Targets in Liver Fibrogenesis

Convention Center: Bluebird Ballroom 3DEF

This session focuses on emerging mechanisms of liver fibrogenesis and novel antifibrotic therapeutic strategies. Topics include hepatic stellate cell activation, extracellular matrix remodeling, metabolic and epigenetic regulation of fibrosis, and innovative cell- and RNA-based therapies. Through mechanistic and translational studies, speakers will highlight new opportunities to prevent, halt, and reverse liver fibrosis.

General Hepatology Update: Contemporary Management of Advanced Liver Diseases—From Metabolic Dysfunction–Associated Steatohepatitis Therapies to Decompensated Cirrhosis

Convention Center: Bluebird Ballroom 2DEF

Join this comprehensive educational program designed to equip clinicians and advanced practice providers with practical, evidence-based approaches across the spectrum of advanced liver disease. Through 3 focused presentations, the program addresses the optimal use of newly approved metabolic dysfunction-associated steatohepatitis therapies; key updates in hepatocellular carcinoma surveillance and management; and contemporary strategies for caring for patients with decompensated cirrhosis.

It Takes Two to Tango: Liver-Kidney, Liver-Heart, Liver-Lung

Convention Center: Bluebird Ballroom 3ABC

This joint symposium from the American Association for the Study of Liver Diseases and the American Society of Transplantation Liver and Intestine Community of Practice highlights the impact of kidney-related, heart-related, and lung-related complications of cirrhosis on liver transplant candidacy, and the role of combined organ transplant.

Redefining Prevention and Management of Portal Hypertension Complications

Convention Center: Mile High Ballroom 2B - 3B

The treatment landscape for portal hypertension complications continues to expand beyond traditional therapies. Advances in pharmacologic management, refinements in TIPS technology, and novel approaches to ascites, encephalopathy, and decompensation prevention are reshaping patient care. This session will present cutting-edge clinical trials evaluating established and emerging therapies and examine how disease-modifying interventions may alter the natural history of cirrhosis.

9 AM - NOON

Point-of-Care Liver Ultrasonography Course: Basic Skills 3

Convention Center: Mile High Ballroom 2C - 3C

This workshop introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice. Participants receive hands-on training for performing POCUS examinations of the liver.

9:45 - 10:15 AM

Inside the Journals: AI in HEPATOLOGY

Convention Center: Summit 2, The Park @TLM, Hall D

Presenters: Naga P. Chalasani, MD, FAASLD

Pediatric Liver Disorders (PLD) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Pediatric Liver Disorders (PLD) SIG.

9:45 - 10:45 AM

AASLD Women Presidents: Pathways to Leadership, Lessons Learned, and Advice for the Next Generation

Convention Center: Room 405 - 407

Take advange of the opportunity to learn from past women presidents of the American Association for the Study of Liver Diseases (AASLD) in this engaging and insightful discussion. Panelists reflect on their individual pathways to leadership, discuss challenges and successes they encountered throughout their careers, and offer guidance for aspiring future leaders.

By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

9:45 - 10:45 AM

AASLD/EASL Masterclass Meet-Up

Convention Center: Summit 5, The Park @ TLM, Hall D

Get ready to connect with your fellow AASLD/EASL Masterclass participants! We're hosting a special meetup for both current and alumni Masterclass participants on Sunday, November 8th from 9:45-10:45am at Meet Up Summit 5. Don't miss this fantastic opportunity to network and make new connections!

Advanced Practice Provider–Led Models in Screening, Treatment, and Care Delivery

Convention Center: Bluebird Ballroom 2DEF

This session highlights the expanding role of advanced practice providers in hepatology, with a focus on MASLD screening, pharmacotherapy implementation, and care delivery innovation. Topics include APP-led lifestyle interventions, pharmacist- and nurse practitioner-driven treatment pathways, AI-assisted diagnostic tools, and the intersection of liver disease with menopause and hormonal therapy.

American Association for the Study of Liver Diseases and Turkish Association for the Study of the Liver (AASLD/TASL): Evolving Challenges in Management of Hepatitis B/Hepatitis D Coinfection and Use of HBsAg–Positive Donor Livers in Transplantation

Convention Center: Bluebird Ballroom 2GH

Chronic hepatitis B virus (HBV) infection remains a major global public health challenge, affecting an estimated 250 million individuals worldwide. Chronic hepatitis B (CHB) is a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. Approximately 5% to 10% of persons with CHB are coinfected with hepatitis D virus (HDV), a defective virus that depends on hepatitis B surface antigen (HBsAg) for its replication and life cycle.

AMH Podcast Recording

Convention Center: Podcast Recording Studio

Beyond the Algorithm: Patient-Informed Decision-Making in Hepatocellular Carcinoma

Convention Center: Room 403 - 404

The landscape of hepatocellular carcinoma (HCC) treatment options has changed dramatically in recent years. There is also increasing recognition of the importance of incorporating patient values, preferences, and patient-reported outcomes (PROs), including health-related quality of life (HRQOL), into treatment decisions.

Clinician and Medical Educators Meet-Up

Convention Center: Summit 6, The Park @ TLM, Hall D

Clinician educators are invited to connect at this Meet-Up. Gather for an hour of informal networking with other TLM attendees to discuss opportunities for collaboration in GME, UME, and CME learning environments as well as in disseminating education scholarship. Interested trainees are welcome.

Liver Transplantation SIG Membership Meeting

Convention Center: Bluebird Ballroom 3ABC

All members of the Liver Transplantation SIG are invited to attend this meeting.

Metabolic Dysfunction–Associated Steatotic Liver Disease and Concomitant Viral Diseases (Human Immunodeficiency Virus, Hepatitis B Virus)

Convention Center: Summit 3, The Park @ TLM, Hall D

Metabolic dysfunction-associated steatotic liver disease (MASLD) increasingly coexists with chronic viral infections, particularly HIV and hepatitis B virus (HBV), creating complex and evolving liver disease phenotypes. This session examines how metabolic dysfunction modifies liver disease progression, fibrosis risk, and clinical outcomes in persons with concomitant HIV and/or HBV infection. The impact of viral infection and antiviral therapies, in turn, influence MASLD natural history.

National Institutes of Health Corner: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Convention Center: Mile High Ballroom 2B - 3B

Join this community conversation about the current work of the US National Institutes of Health, National Institute of Alcohol Abuse and Alcoholism. Key topics include: the potential adverse health risks posed by alcohol at all levels of use, particularly among special populations (eg, women and adults older than 65 years); alcohol use screening and treatment follow-through; and the importance of eliminating stigma to the success of screening and treatment programs.

The Funding Edge: Thriving in Today's Research Climate

Convention Center: Summit 4, The Park @ TLM, Hall D

In a research environment defined by shifting priorities, tighter budgets, and increasing competition, securing research funding has become more challenging. This practical seminar helps researchers at all career stages navigate these changes and strategically pursue funding opportunities with confidence. Presenters provide attendees with actionable tools for identifying aligned opportunities, strengthening proposal competitiveness, and building partnerships that enhance funding success.

Transplant Hepatology and Gastroenterology: 2026 Maintenance of Certification Updates

Convention Center: Bluebird Ballroom 3GH

This informative session enables attendees to gain knowledge of the new 2026 American Board of Internal Medicine maintenance of certification requirements and updates, along with newly available pathways and strategies to more effectively prepare for certification.

Podcast recording.

SUNDAY, NOVEMBER 8

10 – 10:45 AM

Unlocking the Potential of a Liver-Directed Treatment

Supported by: Madrigal

Convention Center: Exhibit Hall F, TLM Theater 1

Unlocking The Potential of a Liver-Directed Treatment, The First and Only treatment for MASH with moderate to advanced fibrosis that activates THR-B.

Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome from Pediatrics to Adults: Genetics, Disease Recognition, and Clinical Management

Supported by: Ipsen

Convention Center: Exhibit Hall F, TLM Theater 2

Through pediatric and adult perspectives, this program will review the genetics, diagnosis, and management of PFIC and Alagille syndrome, providing practical insights to support care across pediatrics and adults and helping clinicians navigate management considerations.

Hep D: From Rare to Aware

Supported by: Mirum Pharmaceuticals

Convention Center: Exhibit Hall F, TLM Theater 3

CHD remains underdiagnosed, with patient identification historically limited by therapeutic options. Yet it's the most aggressive form of viral hepatitis, with the worst outcomes when untreated. Join an interactive session with leading hepatologists and a person living with CHD to explore the diagnostic journey, care gaps, and evolving treatment landscape.

10:15 – 10:45 AM

Acute on Chronic Liver Failure (ACLF) SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Acute on Chronic Liver Failure (ACLF) SIG.

Inside the Journals: Recompensation of Decompensated Cirrhosis in MASLD and MetALD

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: K. Rajender Reddy, MD, FAASLD

11 – 11:30 AM

Thomas E. Starzl Transplant Surgery State of the Art: Normothermic Machine Perfusion

Convention Center: General Session, Hall A

Reviews advances in normothermic machine perfusion and its evolving role in organ preservation, assessment, and transplantation.

11 AM – 12:30 PM

Beyond the Liver: Addressing Burnout in Hepatology Practice

Convention Center: Bluebird Ballroom 3ABC

This thought-provoking program aims to help the practicing hepatologist understand the definition and impact of burnout. A recent survey of 185 transplant hepatologists in the US and found that 40% experienced emotional exhaustion, a significant predictor of burnout.* Therefore, this session not only includes methods to recognize early warning signs of burnout and help distinguish it from stress and depression, it also focuses on tips to combat burnout.

Cellular and Molecular Drivers of Liver Homeostasis, Injury, and Regeneration

Convention Center: Bluebird Ballroom 2DEF

This session highlights cutting-edge discoveries in liver biology and disease, showcasing novel molecular mechanisms that regulate liver cell identity, injury responses, fibrosis, bile acid metabolism, and regeneration. Presentations explore innovative therapeutic approaches, including exosome-based delivery systems, machine learning-driven cell engineering, and pharmacologic modulation of regenerative pathways, that advance our understanding of liver homeostasis and repair.

Clinical Trial Pipeline for MASH 2026

Convention Center: Bluebird Ballroom 1A

This session on the MASH clinical trial pipeline explores the rapid evolution of drug development. It covers emerging molecules in the pipeline, mechanisms of action, and late-stage trial endpoints addressing fibrosis and cirrhosis.

Current Therapeutic Strategies in MASH: Lifestyle and Pharmacologic Interventions

Convention Center: Bluebird Ballroom 1A

This session examines pharmacologic (GLP-1 agonists, resmetirom) and lifestyle-based interventions for MASH/MASLD across adult and pediatric populations, including transplant recipients.

Does One Size Fit All? Considerations for Incretin Use in Special Populations

Convention Center: Mile High Ballroom 2A - 3A

Metabolic syndrome and obesity are increasingly prevalent among persons with liver disease, particularly in those with metabolic dysfunction-associated steatotic liver disease (MASLD). As hepatologists incorporate powerful incretin therapies into their treatment arsenal, understanding their optimal use in diverse and special populations becomes essential-and is the focus of this session.

By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

11 AM – 12:30 PM

Emerging and Repurposed Therapeutics in Alcohol-Associated Liver Disease

Convention Center: Bluebird Ballroom 1B

This session surveys the expanding therapeutic landscape in alcohol-associated liver disease across the translational spectrum. Presentations span phase 2 trial data on incretin-based agents (zalfermin, cagrilintide, semaglutide) and target trial emulation of GLP-1 receptor agonists in decompensated cirrhosis, alongside preclinical studies of the repurposed PDE4 inhibitor roflumilast and examination of Rifaximin's potential to impact the microbiome to reduce fibrosis progression in ALD.

Gut Liver Axis and Microbiome

Convention Center: Bluebird Ballroom 3DEF

This session explores microbiome-liver interactions across disease states, including virome and metagenomic signatures in PSC, gut-derived metabolites in fibrosis, and microbiome-linked mechanisms in alcohol-related hepatitis.

Hepatobiliary Neoplasia 1: Clinical Behaviors

Convention Center: Bluebird Ballroom 2ABC

This session presents advances in HCC detection and prognostication, including deep learning imaging models, circulating biomarkers, and structured surveillance program outcomes.

Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries

Convention Center: Mile High Ballroom 2B - 3B

This session covers advances in inherited metabolic liver diseases - Wilson disease, alpha-1 antitrypsin deficiency, and acute hepatic porphyria - including natural history data and emerging targeted therapies.

Precision Diagnosis and Dynamic Risk Stratification in Portal Hypertension

Convention Center: Bluebird Ballroom 1C

The management of portal hypertension is rapidly evolving from static staging paradigms toward dynamic, individualized risk assessment, evolving guidelines, and deeper understanding of treatment response and disease regression.

11:30 AM – 12:30 PM

Liver Transplant Plenary

Convention Center: General Session, Hall A

The recent increase in the global utilization of normothermic machine perfusion is changing day-to-day practice of liver transplantation, with new logistics and complexities.

12:30 – 1 PM

Steatotic Liver Disease: Completing the Care Mosaic—From Missed Diagnosis to Better Outcomes

Supported by: GSK

Convention Center: Exhibit Hall F, TLM Theater 1

Steatotic liver disease represents a substantial clinical and public health burden. This program will examine the role of non-invasive tests in the identification and referral of patients, explore approaches to enhancing early intervention and review the evidence supporting fibrosis regression as a key objective to improve patient outcomes.

Advancing Management Goals in Primary Biliary Cholangitis (PBC): Biochemical Control, Residual Risk and Symptom Burden

Supported by: Ipsen

Convention Center: Exhibit Hall F, TLM Theater 2

This interactive case-based session explores the evolving management goals in primary biliary cholangitis (PBC), highlighting the limitations of traditional biochemical response thresholds and the importance of residual risk assessment. Through real-world patient scenarios, faculty will examine alkaline phosphatase normalization, symptom burden, and comprehensive management strategies.

12:30 – 2 PM

From Uncertainty to Accuracy: Optimizing Outcomes in Adult Genetic Cholestatic Liver Diseases

Supported by: Mirum Pharmaceuticals
Organized by: Medscape Education

Convention Center: Four Seasons Ballroom 2 - 3

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) frequently present diagnostic challenges in adult clinical practice due to late-onset manifestations and overlapping systemic features. Key focus areas include diagnostic evaluation strategies to recognize adult-onset disease, characterization of hepatic and extrahepatic complications, and implementation of coordinated interprofessional care models. Additionally, evidence-based approaches for selecting targeted management strategies address bile acid accumulation, severe pruritus, and long-term hepatic outcomes. Interactive case-based analysis illustrates essential decision points to optimize clinical recognition, disease monitoring, and overall patient management.

Podcast recording.

SUNDAY, NOVEMBER 8

12:30 – 2 PM

Navigating the Nuances of Pruritus: An Expert Panel on Complex Cases in PBC Symptom Management

Supported by: Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.
Organized by: Chronic Liver Disease Foundation (CLDF)
CME Provided by: University of Cincinnati

Convention Center: Four Seasons Ballroom 4

This symposium offers expert perspectives and practical insights for navigating complex primary biliary cholangitis (PBC) pruritus cases and optimizing individualized patient care. Faculty will review challenging, real-world cases and examine nuanced clinical decision-making beyond first-line management, including differential diagnosis, available treatment options, and the interconnected burden of itch, fatigue, and quality of life.

The Metabolic MASH-UP – What's New and What's Hot

Supported by: Inventiva
Organized by: Medscape Education

Convention Center: Four Seasons Ballroom 1

The rising tide of metabolic disease has triggered a concurrent epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Despite this growing clinical burden, critical gaps remain in clinical awareness regarding disease prevalence,x long-term consequences, effective risk assessment, and evidence-based management. With multiple novel therapeutic agents rapidly advancing through clinical trials for MASH, it is essential for clinicians to stay updated on these emerging treatment paradigms. Join us in this live exchange with the experts in the field to: Interpret emerging clinical data regarding new and developmental therapies for MASH. Develop individualized treatment strategies tailored to a patient's specific degree of liver fibrosis, steatosis, and concurrent metabolic comorbidities.

Women's Networking Luncheon

Supported by: Gilead Sciences and Madrigal

Convention Center: Room 405 - 407

Women's Networking Luncheon - An exclusive luncheon bringing together women shaping the future of Hepatology. Engage in candid conversations about navigating the field, exchange insights with other leaders, and cultivate connections that extend well beyond the conference.

12:45 – 1:30 PM

FGF21 Analogs in Focus: From Pathways to Clinical Evidence in MASH

Supported by: Novo Nordisk

Convention Center: Exhibit Hall F, TLM Theater 3

During this interactive session, Drs Arun Sanyal and Kris Kowdley will be highlighting current gaps in the management of steatotic liver disease, reviewing the mechanisms of FGF21 analogs in MASH and discussing the clinical evidence for FGF21 analogs in MASH management.

MTE #29: Seeing Through the Haze—Mastering Noninvasive Tools for Fibrotic Metabolic Dysfunction–Associated Steatohepatitis

Convention Center: Room 1A

Accurate identification of fibrotic metabolic dysfunction-associated steatohepatitis (MASH) is critical for risk stratification, treatment selection, and referral. Liver biopsy, however, is neither feasible nor appropriate for most patients. Faculty provide a practical, case-based discussion of noninvasive approaches to detecting fibrotic MASH including serum-based scores, elastography, and emerging biomarkers.

MTE #30: Cut to the Case—Delivering Complex Liver Patient Presentations in Minutes

Convention Center: Room 1B

In multidisciplinary settings-such as transplant selection meetings, tumor boards, and daily rounds-time is limited yet decisions are critical. How do you present a complex patient's story concisely without losing essential details? Join seasoned experts for an interactive, informal roundtable discussion on strategies to streamline case presentations while maintaining clinical accuracy and impact.

MTE #31: Preclinical Models of Alcohol-Associated Liver Disease and Hepatotoxicity

Convention Center: Room 1C

Alcohol-associated liver disease (ALD) is a leading cause of chronic liver injury worldwide and comprises a range of disorders including simple steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. This session explores various animal models that have been developed for the study of ALD pathogenesis. Presenters review a recently developed chronic plus binge ethanol feeding model, which induces significant steatosis, hepatic neutrophil infiltration, and liver injury.

MTE #32: Bridging to Transplant in Hepatocellular Carcinoma—Immunotherapy, Locoregional Therapy, or Both?

Convention Center: Room 1D

Immune checkpoint inhibitors (ICIs) have reshaped the treatment paradigm of hepatocellular carcinoma (HCC), delivering improvements in tumor responses and survival benefits in those with advanced disease. Simultaneously, liver transplantation remains the most effective curative strategy for selected perons with HCC.

By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

12:45 – 1:30 PM

MTE #33: Metabolic-Immune Coupling in Liver Disease

Convention Center: Room 1E

Join this expert session to discuss how metabolic dysregulation modulates the immune response. Topics addressed include:

- The immunological landscape in metabolic liver diseases
- Mechanisms linking metabolic injury to inflammation, such as lactate and fatty acid modulation of immune cells and cholesterol-driven inflammasome activation
- Potential targets for therapeutic intervention
- Challenges in immunoregulatory strategies

MTE #34: Molecular Regulation of Hepatic Stellate Cell Activation During Liver Injury and Fibrosis

Convention Center: Room 1F

In this interactive session, experts discuss recent advances in hepatic stellate cell (HSC) biology in the context of liver injury and fibrosis progression. Quiescent HSCs play a critical role in liver homeostasis whereas activated HSCs are associated with fibrogenesis. Studies have identified distinct HSC populations that play differential roles during liver injury, tissue homeostasis, and fibrosis.

MTE #35: Getting Started With Health Services Research and Quality Improvement

Convention Center: Room 4A

This informal introductory expert session orients learners to the field of health services research (HSR) and quality improvement (QI). Faculty provide an overview of what HSR and QI are, why they matter, and how they are used to improve the quality, accessibility, and fairness of health care.

1 – 1:30 PM

Inside the Journals: Liver Cancers—The Multi-modal Path to Precision Care

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Sumera I. Ilyas, MD

Portal Hypertension: Clinical and Experimental SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Portal Hypertension: Clinical and Experimental SIG.

1 - 2 PM

Developing and Cultivating Your Research Portfolio

Convention Center: Summit 3, The Park @ TLM, Hall D

Join this informative session focused on developing and cultivating a research portfolio. Topics include National Institutes of Health (NIH) research opportunities, cultivating mentoring relationships, and building a successful research program. The presentations are followed by an interactive discussion period.

Sunday Poster Presenter Presentation Hour

Convention Center: Poster Hall, Hall DE

The following poster categories will be in the Poster Hall:

- Hepatitis B
- Hepatobiliary Neoplasia
- Liver Transplantation and Liver Surgery

The Editors Cut: Highlights From Liver Transplantation

Convention Center: Summit 4, The Park @ TLM, Hall D

Join faculty for this session designed for a broad audience, including transplant hepatologists, transplant surgeons, clinical hepatologists, residents, fellows, and students. Presenters highlight updates from the most noteworthy publications addressing liver transplantation in the setting of hepatocellular carcinoma, cholangiocarcinoma, metabolic dysfunction-associated steatotic liver disease, and alcohol-associated liver disease, as well as recent surgical advances.

1:30 – 2 PM

Hepatology Associates SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Hepatology Associates SIG.

Inside the Journals: AASLD EXPO on Hepatitis Delta Virus

Convention Center: Summit 2, The Park @TLM, Hall D

Presenter: Jordan J. Feld, MD, MPH, FAASLD

More Than Fat in the Liver: Understanding the Metabolic Impact of MASLD and MASH

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.

Convention Center: Exhibit Hall F, TLM Theater 1

This program explores the risks associated with MASLD/MASH, why early screening for liver fibrosis is needed in at-risk patients like those with obesity, and why metabolic drivers should be addressed as part of MASH care.

Podcast recording.

SUNDAY, NOVEMBER 8

1:30 – 2 PM

Peer to Peer Series on Wilson Disease: Unmet Needs in Wilson Disease, Strategies for Long Term-Management, and the Role of CUVRIOR

Supported by: Orphalan, Inc.

Convention Center: Exhibit Hall F, TLM Theater 2

Join us for an informative presentation on Wilson disease. This promotional peer-to-peer discussion will explore unmet needs in Wilson disease, strategies for long-term management, and the role of an approved treatment option.

2 – 3:30 PM

AASLD/KASL Community Conversation: Redefining Risk in Chronic Liver Disease

Convention Center: Bluebird Ballroom 2GH

This community conversation between the American Association for the Study of Liver Diseases and the Korean Association for the Study of the Liver addresses a fundamental question in hepatology: How do we better identify which patients with chronic liver disease are at highest risk? Leading experts from both organizations discuss 3 areas where the approach to risk assessment is changing.

Alcohol-Associated Liver Disease: From Prediction and Phenotyping to Transplantation and Population Trends

Convention Center: Bluebird Ballroom 1B

This session presents advances across the spectrum of alcohol-associated liver disease. Talks span novel risk-stratification and mortality-prediction tools (an explainable AI decision-support model, metabolic/quantitative-fibrosis histophenotyping, and decompensation in AH), evolving practices in early liver transplantation, and pre-transplant psychosocial evaluation.

Clinical Research Workshop, Part 1: What's New in Cirrhosis Management—Shifting Paradigms and Implications for Clinical Research

Convention Center: Bluebird Ballroom 2ABC

This workshop highlights the evolving landscape of cirrhosis diagnosis and management, and explores how these changes are reshaping clinical research. Faculty challenge the traditional approaches to hepatocellular carcinoma (HCC) screening, and portal hypertension assessment and management. Presenters discuss the evolving concept of cirrhosis recompensation with a focus on implications for clinical trial design, end points, and patient stratification.

Health Equity in Chronic Liver Diseases in the United States

Convention Center: Mile High Ballroom 2B - 3B

This session presents current research on health disparities and health equity in chronic liver diseases in the United States. Topics include disparities in treatment access, rural versus urban outcomes, the role of social determinants of health in surveillance and therapy, patient portal engagement, and shifting drivers of liver cancer.

Hepatitis - Other Infections

Convention Center: Bluebird Ballroom 2DEF

This session focuses on chronic hepatitis D (delta), covering emerging therapies (bulevirtide, lonafarnib, novel entry inhibitors) and international epidemiologic data.

Hepatobiliary Neoplasia 2. Enhancing Treatment

Convention Center: Bluebird Ballroom 1C

This session reviews systemic and locoregional treatment strategies for advanced HCC, including network meta-analyses of combination therapies, AI-assisted tumor board support, and multidisciplinary decision-making outcomes.

Hepatotoxicity

Convention Center: Bluebird Ballroom 3DEF

This session covers drug-induced liver injury across multiple contexts - statins, checkpoint inhibitors, acetaminophen, and GLP-1 agonists - using registry data, organoid models, and AI-based case triage tools.

Inflammation and Immunobiology

Convention Center: Bluebird Ballroom 3DEF

This session presents mechanistic studies of hepatic immune regulation, covering macrophage polarization, T cell responses in transplantation and cirrhosis, and circadian regulation of ischemia-reperfusion injury.

Late Breaking Abstract Parallel Session 1

Convention Center: General Session, Hall A

Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.

Liver Disease in People Living With Human Immunodeficiency Virus: Across the Continuum of Care

Convention Center: Mile High Ballroom 2A - 3A

Liver disease remains one of the most important comorbidities affecting people living with HIV and continues to be a leading contributor to non-AIDS-related morbidity and mortality. While advances in antiretroviral therapy have transformed HIV into a chronic condition, the burden of liver disease has expanded beyond viral hepatitis to include metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease, and advanced cirrhosis.

By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

2 – 3:30 PM

Point-of-Care Liver Ultrasonography Course, Advanced Skills 2

Convention Center: Mile High Ballroom 2C - 3C

This workshop provides advanced training for use of liver point-of-care ultrasonography (POCUS). It is intended for professionals who have previously completed the Basic Skills Liver POCUS course at The Liver Meeting or Digestive Disease Week. The workshop includes a theoretical portion focusing on assessment of inpatient liver findings using POCUS, liver elastography, and advice on implementing liver POCUS in clinical practice.

Transplant in the Public Eye: Ethics of Liver Donation and Transplantation

Convention Center: Bluebird Ballroom 3ABC

Explore the ethical challenges shaping contemporary liver transplant practice amid increasing public scrutiny, limited resources, and evolving technologies. This multidisciplinary session examines how innovations such as donation after circulatory death (DCD), machine perfusion, and living donation intersect with ethical obligations to donors, recipients, and society.

3:30 – 4:15 PM

ALP +me: Daily Life Informing Management of PBC

Supported by: Ipsen Biopharmaceuticals

Convention Center: Exhibit Hall F, TLM Theater 2

What can patients living with primary biliary cholangitis (PBC) teach us about how they successfully manage the condition? Hear expert and patient perspectives on practical ways to recognize, assess and monitor PBC symptoms to better inform patient-centered care.

MASH Matters: The Role of the Liver in Metabolic Health

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.

Convention Center: Exhibit Hall F, TLM Theater 1

Join our Boehringer Ingelheim-sponsored Product Theater to hear more about the role of the liver in metabolic dysfunction, including a discussion on the broader impact beyond the liver. Our esteemed panel will also highlight the latest in MASLD/MASH patient management and answer your questions.

Small Diameter Stents Widen Options – Reconsidering When and Who to TIPS

Educational Discussion Supported by W. L. Gore & Associates

Convention Center: Exhibit Hall F, TLM Theater 3

Join transplant hepatologist Dr. Brett Fortune and interventional radiologist Dr. Bartley Thornburg as they share real-world experience and case studies using small diameter TIPS. Explore how stent options for patients with ascites and variceal bleeding are influencing patient selection, referral timing, complications like HE, and procedural outcomes.

3:45 – 4:15 PM

Liver Fibrosis & Cirrhosis SIG Poster Highlights

Convention Center: Summit 1, The Park @ TLM, Hall D

Join us for a poster highlight of the top abstracts from the Liver Fibrosis & Cirrhosis SIG.

3:45 – 4:45 PM

A Community Conversation With the American Association for the Study of Liver Diseases Journal Editors

Convention Center: Bluebird Ballroom 3GH

Join journal editors from Hepatology, Hepatology Communications, and Liver Transplantation for an interactive community conversation tailored to residents, fellows, junior faculty, and students. Expect a pragmatic mix of brief talks and an extended open discussion focused on how to craft compelling manuscripts, what editors look for in submissions and review articles (basic and clinical), and how to navigate decisions and revisions with confidence.

American Association for the Study of Liver Diseases and Taiwan Association for the Study of the Liver (AASLD/TASL) Community Conversation: Precision Management of Chronic Hepatitis B

Convention Center: Bluebird Ballroom 2GH

This year's American Association for the Study of Liver Diseases and Taiwan Association for the Study of the Liver joint community conversation program highlights updates on the current status, regional and shared challenges and unmet needs, and emerging strategies toward precision management of chronic hepatitis B.

Clinical Research Workshop, Part 2A, Breakout Sessions: Noninvasive Tools for Compensated Advanced Chronic Liver Disease and Portal Hypertension—Use in Daily Clinical Practice

Convention Center: Bluebird Ballroom 2ABC

This workshop highlights the evolving landscape of cirrhosis diagnosis and management, and explores how these changes are reshaping clinical research. Faculty challenge the traditional approaches to hepatocellular carcinoma (HCC) screening, and portal hypertension assessment and management. Presenters discuss the evolving concept of cirrhosis recompensation with a focus on implications for clinical trial design, end points, and patient stratification.

Podcast recording.

SUNDAY, NOVEMBER 8

3:45 – 4:45 PM

Clinical Research Workshop, Part 2B, Breakout Sessions: Recompensation in Alcohol-Associated Liver Disease—Predictive Factors, Management, and Gaps in Knowledge for Future Research

Convention Center: Bluebird Ballroom 2DEF

This workshop highlights the evolving landscape of cirrhosis diagnosis and management, and explores how these changes are reshaping clinical research. Faculty challenge the traditional approaches to hepatocellular carcinoma (HCC) screening, and portal hypertension assessment and management. Presenters discuss the evolving concept of cirrhosis recompensation with a focus on implications for clinical trial design, end points, and patient stratification.

Clinical Research Workshop, Part 2C, Breakout Sessions: Screening for Hepatocellular Carcinoma in 2026 and Beyond—Challenges for Clinical Research

Convention Center: Bluebird Ballroom 3DEF

This workshop highlights the evolving landscape of cirrhosis diagnosis and management, and explores how these changes are reshaping clinical research. Faculty challenge the traditional approaches to hepatocellular carcinoma (HCC) screening, and portal hypertension assessment and management. Presenters discuss the evolving concept of cirrhosis recompensation with a focus on implications for clinical trial design, end points, and patient stratification.

Program Directors Workshop

Convention Center: Room 405 - 407

Join faculty to learn about the current state of advanced hepatology training and to discuss topics relevant to retention and growth of the hepatology workforce. Topics include models to fulfill the American Board of Internal Medicine (ABIM) requirements for the transplant hepatology fellowship; hepatology focused gastroenterology ABIM recertification pathway options for the longitudinal knowledge assessment (LKA); and updates on nontraditional pathways and exceptions within ABIM.

Recompensation: For Whom, When, and Why?

Convention Center: Room 403 - 404

The current definition of recompensation, established at the Baveno consensus several years ago, was largely based on expert opinion at a time when robust longitudinal data were limited. Since then, accumulating clinical evidence has begun to redefine the concept of recompensation, suggesting that a broader and more heterogeneous group of patients may experience meaningful and sustained improvement.

5 – 6:30 PM

AASLD/JSH Joint Session: Evolving Strategies in Liver Cancer Management—Prevention, East Versus West

Convention Center: Bluebird Ballroom 2GH

Jointly presented by the American Association for the Study of Liver Diseases and the Japan Society of Hepatology, this progam is the second of 2 sessions with the shared goal of reviewing evolving strategies in liver cancer management in Eastern and Western regions. The first session, presented at Japan DDW 2026 in Kobe, Japan, focused on liver cancer treatment. This second session focuses on the prevention of liver cancer in persons with viral and metabolic liver diseases.

Genomics and Precision Medicine

Convention Center: Bluebird Ballroom 2DEF

This session presents genomic and molecular discoveries in liver disease, spanning cirrhosis risk loci, single-cell/spatial transcriptomics in hepatoblastoma, and population-scale genetic variant studies in MASLD and HCC.

Health Equity, Care Models, and Predictive Tools in Hepatology

Convention Center: Bluebird Ballroom 3DEF

This session addresses disparities and structural barriers in liver disease care, along with predictive/ML-based tools and novel care delivery models (telehealth, quality measures) to improve outcomes.

Hepatitis C: Risk Stratification and Public Health Strategies

Convention Center: Bluebird Ballroom 3ABC

This session covers post-SVR risk stratification for HCC and liver-related outcomes in hepatitis C, plus novel diagnostics and public health strategies for testing and treatment in high-risk populations.

Hepatobiliary Neoplasia 3: Response or Resistance to Therapy

Convention Center: Bluebird Ballroom 1C

This session examines mechanisms of treatment resistance in hepatobiliary cancers, including tumor microenvironment and immune evasion pathways driving resistance to immunotherapy.

By invitation only. Ticket required. AASLD members only.

SUNDAY, NOVEMBER 8

5 – 6:30 PM

Late Breaking Abstract Parallel Session 2

Convention Center: General Session, Hall A

Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.

Liver Transplant: Access, Disparities and Allocation

Convention Center: Mile High Ballroom 2A - 3A

This session examines the structural, geographic, and clinical factors that shape who gains access to liver transplantation and how organs are allocated. Presentations address disparities across the transplant continuum-from waitlist mortality risk and MELD-based allocation to the influence of public perception on donation-highlighting opportunities for more equitable practice. Together, these studies offer evidence to inform allocation reform and reduce inequities in transplant access.

Optimizing Organ Utilization: Machine Perfusion, Donor Selection & Graft Outcomes

Convention Center: Mile High Ballroom 2B - 3B

This session highlights advances in expanding and optimizing the donor organ pool through machine perfusion, refined donor selection, and improved risk prediction. Presentations span the transplant pathway-from DCD procurement decisions and normothermic machine perfusion strategies to graft-threatening complications and downstaging protocols for HCC-with an emphasis on interpretable modeling and translational interventions.

PSC and Autoimmune Liver Disease: Disease Modifiers and Clinical Outcomes

Convention Center: Bluebird Ballroom 2ABC

This session examines factors modifying disease course in PSC and autoimmune hepatitis, including alcohol exposure, statin use, pruritus therapies, and post-transplant recurrence risk.

The Liver Meeting Debrief 1: Pediatric Liver Disease, Liver Transplantation, and Portal Hypertension

Convention Center: Bluebird Ballroom 1A

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 1 covers pediatric liver disease, liver transplantation, and portal hypertension.

What's Next in Hepatology? Breakthroughs in Prediction, Diagnosis, and Patient Outcomes

Convention Center: Bluebird Ballroom 1B

This session showcases emerging prediction and diagnostic tools across hepatology, including AI-assisted guideline synthesis, novel fibrosis risk scores, and exercise-based interventions in cirrhosis.

AASLD ADVOCACY

SEE AASLD ADVOCACY IN ACTION

Stop by the Advocacy Pod to see how AASLD and its members are turning advocacy into action, from Capitol Hill and liver health events to thousands of messages sent directly to policymakers. Explore the impact we're making and see how you can add your voice.

Podcast recording.

MONDAY, NOVEMBER 9

8 - 10:30 AM

The Liver Meeting Debrief 2: Basic Science, Hepatitis, Hepatocellular Carcinoma, Cholestatic Liver Disease, Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD

Convention Center: General Session, Hall A

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 2 addresses basic science research, hepatitis, hepatocellular carcinoma, cholestatic liver disease, metabolic dysfunction-associated liver disease, alcohol-associated liver disease, and MetALD.

10:30 AM - NOON

Late Breaking Abstract Parallel Session 3

Convention Center: General Session, Hall A

Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.

AASLD & AASLD FOUNDATION BOOTH



The AASLD and AASLD Foundation Hub is the connection point for everything AASLD and AASLD Foundation have to offer. Located at the entrance to #TLM26, the space takes you on a journey of learning, community, and impact showcasing how they *ELEVATE* the hepatology field and advance efforts to prevent and cure liver disease.





OPEN TO ALL
AASLD MEMBERS

AASLD

MEMBERS' RECEPTION

FRIDAY, NOVEMBER 6
7:30-11:30PM

DENVER ART MUSEUM
100 W 14TH AVE PKWY,
DENVER, CO

SUPPORTED
IN PART BY

mirum
inventiva
elevar therapeutics

ATTENDEES MUST WEAR THEIR BADGES TO ATTEND.

AASLD The Liver Meeting®

LET THE LIVER QUEST BEGIN!

Starting Thursday through Sunday, turn your #TLM26 experience into an adventure! Solve daily clues, locate the QR codes, and scan for a chance to win daily prizes.

OPEN THE TLM APP TO START WINNING TODAY!



1 READ THE CLUES FOR THE DAY

Delivered to your inbox through the Daily News ***and*** *daily mobile app notification.*

2 LOCATE EACH QR CODE

Find the QR code featuring the ***Liver Quest wizard.***

3 SCAN USING THE TLM26 MOBILE APP

Use the TLM26 mobile app to scan each QR code and ***earn five points toward that day's challenge.***

4 COMPLETE THE QUEST BY 7 PM MT

Complete that day's challenge by 7 PM MT to be entered to win.

Prizes include AASLD branded apparel, popular Denver items, and even a complimentary regular registration to TLM27 in Philadelphia.

ELEVATING THE EXPERIENCE: THANK YOU, 2026 SPONSORS!

GOLD SPONSORS

ALFASIGMA

Boehringer Ingelheim

GSK

IPSEN

Madrigal

mirum

NOVO

SPONSORS

Answers in CME LIVE

altimmune

Obesity Association
A division of the American Diabetes Association®

ATEA Pharmaceuticals

BD

CLDF
Chronic Liver Disease Foundation

Eisai

elevar therapeutics

FUJIFILM

Genentech
A Member of the Roche Group

GILEAD

GLI Global Liver Institute

GORE

inventiva

Lilly A MEDICINE COMPANY

Medscape EDUCATION

Orphalan Innovation for Orphan Diseases

goto IPER.com

SIEMENS Healthineers

Takeda

VOX media

zydus Therapeutics

#TLM26 sponsors as of October 13, 2026.

EXHIBIT HALL: INNOVATION ELEV

Connect with leading liver health exhibitors and discover solutions elevating the field.

COMPANY NAME	BOOTH NUMBER
AASLD	772
AASLD - Global Partners	1037
Abbot Cancer Diagnostics	1966
AbbVie	2163
AcariaHealth Specialty Pharmacy	1566
ALEH (Latin American Association for the Study of the Liver)	1140
Alexion	1154
ALFASIGMA	1334, MR35
Aligos Therapeutics	2263, MR31
All the Feelings with PBC	2058
Almac Group	1761
Alpha-1 Foundation	1040
Altimmune	956, MR46
American Diabetes Association	851
American Liver Foundation	854
American Porphyria Foundation	937
Amgen	1236
Amsety LLC	1250

ATED

COMPANY NAME	BOOTH NUMBER
Asian Pacific Association for the Study of the Liver (APASL)	1141
AstraZeneca	950, MR20, MR24, MR45
Atea Pharmaceuticals	1854, MR30
Autoimmune Hepatitis Association	840
Avant Sante Research Center S.A de C.V.	1348
Banner Health	1745
Baylor Scott & White Health	1235
BD	1666
BioPorto Diagnostics	1352
BioPredictive	1652
Blue Faery	1041
Boehringer Ingelheim International GmbH	MR1, MR9
Boehringer Ingelheim	770, MR10, MR2
Cholangiocarcinoma Foundation	1035
Chronic Liver Disease Foundation	941
Cima Sciences	1960
Coalition For Global Hepatitis Elimination, Task Force For Global Health	834
Community Liver Alliance	838

#TLM26 exhibits as of October 13, 2026.

COMPANY NAME	BOOTH NUMBER
Cytotheryx, Inc.	1764
Diasorin	2168
Dose	1238
Dynavax, a Sanofi Company	966
Echosens	1163
Eisai Inc.	2066
EIT Pharma, Inc.	1542
Elevar Therapeutics	1744
Eli Lilly and Company	1758, MR29, MR49, MR50
Eton Pharmaceuticals	1958
European Association for the Study of the Liver (EASL)	1138
fatty15	1954
Fibronostics- LiverFASt	1234
Forum for Collaborative Research	837
Forus (previously Tandem)	1862
Froedtert ThedaCare Health	1642
FUJIFILM Healthcare Americas Corporation	1963
Fujifilm VisualSonics Inc	1863
Gastroenterology & Endoscopy News	1266
Gastro-Hep Communications Inc	1159
GE HealthCare	1354
Genentech	1341, MR19
Gilead Sciences, Inc.	2071, MR21, MR22, MR42, MR43
Global Liver Institute	934

COMPANY NAME	BOOTH NUMBER
Gore & Associates	1866
GSK	761, MR13, MR6
HealthWell Foundation	850
Helio Genomics	1548
HepQuant	1153
HISKY Medical	1550
HistoIndex	2068
HistoSonics Inc	955
ICON	1861
IIAM	1135
ImCare Biotech	2061
InBody	1541
International Liver Transplantation Society	1134
Inventiva	1344, MR26, MR48
IPSEN	1368, MR32, MR33, MR52, MR53, MR54
Keenova Therapeutics	2063
Keenova Therapeutics Medical Affairs	1766
KlinEra	957
Kompetitive LLC	857
Labcorp	1066
Liver Education Advocates	844
Liverpool Drug Interactions	853

#TLM26 exhibits as of October 13, 2026.

COMPANY NAME	BOOTH NUMBER
LiverRight	2267
Livivos Inc	1053
Madrigal	1358, MR3, MR4, MR5, MR11, MR12, MR41
MASH Across America brought to you by Madrigal Pharmaceuticals	1934
Medvex	1747
Metabolic Solutions	1241
Metabolon	1748
Metware Biotechnology Inc	1166
Miltenyi Biotec	1261
Mindray	1754
mirum	1772, MR14, MR15
Mobilis	1451
Natera	1547, MR16
Nebraska Medicine	2269
Northwell Health	1240
Northwestern Medicine	866
novo	1044, MR18, MR39
Orphalan US	1173, MR40
OU Health-The University of Oklahoma	1351
PathAI	1158, MR51

COMPANY NAME	BOOTH NUMBER
Patient Advocate Foundation	938
PBC Awareness	935
PBC Foundation	940
PBCers Organization	842
Pedestal Health	1968
Perspectum	1055, MR56
PFIC Network, Inc.	846
PharmaLegacy Laboratories Co., Ltd.	1641
PhoenixBio	766
PLEXISION,INC	1648
Practice Edge	1452
Precisionary Instruments LLC	2166
Prometheus Laboratories	2268, MR38
PSC Partners Seeking a Cure	1034
Recordati Rare Diseases	1466
REGENERON	1544, MR28
Remedy Specialty Network	1749
Research Diets Inc.	1366
Resolution Therapeutics	2266
Resoundant Inc.	1258
Revvity	953
Rocky Mountain Poison and Drug Safety	848
Salix Pharmaceuticals	1768

#TLM26 exhibits as of October 13, 2026.

COMPANY NAME	BOOTH NUMBER
SASLT (Saudi Society for the Study of Liver Diseases and Transplantation)	735
Siemens Healthineers	1150, MR25
SOLDA (Society on Liver Disease in Africa)	1136
Sonic Incytes	1454
SoQut Imaging	2167
Taconic Biosciences	1763
Takeda	1068
Takeda Transplant	1161
Tampa General Hospital	1647
Texas Liver Care	856
Thermo Fisher Scientific	1651
United Porphyrias Association	845
UPMC Presbyterian	1864
VA Pittsburgh Health System	841
Vir Biotechnology, Inc.	1253, MR27, MR47
Virtua Health	847
WuXi AppTec	1955
Zydus Therapeutics Inc	1554, 1650, MR37

VIEW THE EXHIBIT HALL MAP ONLINE, SCAN NOW

#TLM26 exhibits as of October 5, 2026.



To learn more, stop by Booth #1854

Committed to Innovation - Advancing Investigational Therapies for the Treatment of HCV, HEV and Other Viral Diseases

Atea is advancing the fixed-dose combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, in the first global Phase 3 head-to-head program of direct-acting antivirals for hepatitis C virus (HCV) infection. C-BEYOND (NCT06868264) met its primary and secondary endpoints. Topline results from C-FORWARD (NCT07037277) are anticipated in early 2027.

The burden of HCV remains high in the US, with as many as 4 million people living with the infection, and 160,000 new cases annually.

In addition to HCV, Atea is developing AT-587, an investigational oral nucleotide analog for hepatitis E virus (HEV) infection, currently being studied in a first-in-human Phase 1 clinical trial (NCT07728487).

Leveraging our deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, and virology, Atea is dedicated to advancing oral antivirals for patients worldwide affected by serious viral diseases.

Bemnifosbuvir, ruzasvir and AT-587 are investigational agents and have not been approved by the FDA or any other regulatory authority for any use.

Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections.

Find out more at
www.ateapharma.com

Copyright © 2026 By Atea Pharmaceuticals
All rights reserved

Atea Pharmaceuticals, Inc.
225 Franklin Street
Suite 2100
Boston, MA 02110

+1 (857) 284-8891

SAVE THE DATE FOR TLM27:
NOVEMBER 12 - 16, 2027
PHILADELPHIA, PA







STAY INFORMED.
SCAN THE QR CODE TO
BOOKMARK THE WEBSITE!

AASLD The Liver Meeting®

NOV. 12–16, 2027

Philadelphia, **PA**